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ABSTRACT

Vielma Delano, Sofia K. M.S., Purdue University, August 2016. An Economic
Assessment of Household Unwanted Medicine Disposal Programs. Major Professor: Dr.
Kwamena K. Quagrainie.

There has been increasing concern about the environmental impact of
pharmaceutical accumulations in surface and groundwater over the last two decades due to
their improper disposal. Improper storage of these pharmaceuticals at home also poses a
public health concern given its association with drug abuse and accidental poisoning.
Several states in the U.S., including those bordering the Great Lakes, have implemented
medicine take-back programs to help mitigate problems associated with unused and
unwanted pharmaceuticals kept in households. Although positive benefits for society and
the environment have been reported for these programs, the perceived monetary value has
not been estimated. This thesis assessed the determinants of household participation in a
medicine take-back program and estimated the value of a pharmaceutical collection
program through a contingent valuation procedure.
An ordered logit model was estimated to assess the factors that can influence
participation in a medicine take-back program. A double hurdle model was then used to
estimate the mean willingness to pay (WTP) per prescription as well as per visit by current
users of the program and potential users in the Great Lakes region.

xi
The dataset used for the study consisted of a sample of 2,031 respondents from a
survey that solicited information about unwanted and unused medicine disposal practices
and willingness to participate in a medicine take-back program. The survey was
administered online in the summer of 2015 to residents of Illinois, Indiana, Michigan,
Minnesota, Ohio and Wisconsin.
The results suggest that young adults with an annual household income above the
national median of $51,759 dollars and environmentally conscious individuals are more
likely to participate in medicine take-back programs. Regarding participation, 60% of
respondents are willing to participate in a collection program, while 40% are willing to pay
to participate in a collection program. The unconditional mean WTP is $0.53 per
prescription and $1.03 per visit, while the mean willingness to pay for those with a positive
willingness to pay is $1.03 per prescription and $2.33 per visit. The total annual value for
such programs in the Great Lakes region is estimated to be between $20.75 and $41.30
million under the WTP per prescription estimations, and $19.70 - $39.25 using the WTP
per visit estimations. This information helps to better inform program providers,
researchers, policymakers, advocates and other interested parties on the value of these
collection programs.

1

CHAPTER 1. INTRODUCTION

This chapter introduces the research project conducted on valuing unwanted
medicine take-back programs in the Great Lakes region. It provides a general overview
motivating the study, followed by the problem statement, and then the general objectives.
Finally, the hypothesis statements are presented.

1.1

Motivation

Pharmaceuticals are used to treat illnesses and diseases in both humans and animals.
In the U.S., prescription1 medicines play a very important role in the health care system.
From 2009-2012, 48.7% of the population used at least one prescription drug within a 30day period, while 21.8% had used three or more over the same period (NCHS, 2014). The
increasing consumption of prescription medicines presents health, safety and
environmental challenges associated with improper storage and disposal of unused and
unwanted pharmaceuticals.
Studies have identified pharmaceutical chemicals in rivers, streams and
groundwater in 71 countries across the world (IWW, 2014), and across the U.S. (Benotti,
et al., 2009, Kolpin, et al., 2002). Pharmaceutical chemicals may also degrade into
constituent compounds that persist in the environment.

1

In the following thesis, “prescription” will refer to both prescription and over-the-counter medications.
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Improper disposal of medicines could result in higher concentrations of active
pharmaceutical ingredients (APIs) in effluents. Households commonly dispose unwanted
or expired drugs by pouring them down the sink or flushing them down the toilet,
eventually entering the wastewater stream. Municipal sewage treatment plants are not
equipped to degrade substances from pharmaceutical products, leading to the eventual
presence of pharmaceuticals in waterways. The introduction and accumulation of
pharmaceutical compounds in the environment is a growing issue, with latent implications
for human health and ecosystems that are still not clearly understood. The Environmental
Protection Agency (EPA) is working with the National Academy of Sciences to advice on
the potential risk to human health from low residues of pharmaceuticals in drinking water.
The Great Lakes, which provide drinking water, recreation, transportation, and industry to
more than 40 million people in the North Central region are no exception to the risks of
such accumulations (Blair, et al., 2013). In addition, the Great Lakes are also home to
diverse and unique basin-wide ecosystems.
Pharmaceutical accumulation and unsafe storage in households can also pose a
public safety hazard. Medicines are one of the most common poison exposure in the
country (Mowry, et al., 2015), increasing the risk of accidental poisoning of children and
pets. Prescription drug abuse and its potential health consequences are also a public health
problem. According to the National Center for Health Statistics (NCHS), drug overdose
death rates have increased five-fold since 1980, becoming the leading cause of accidental
deaths in 29 states and Washington D.C. (NCHS, 2014). The estimated cost to the nation
include lost productivity, medical costs and criminal justice costs, which amounts to $53.4
billion a year (NCHS, 2014).

3
Several states and counties across the Unites States have implemented medicine
take-back schemes to mitigate the problems associated with unused and unwanted
medications. Medicine take-back programs provide secure collection points and
environmentally sound destruction of unwanted medicines to protect public health and the
environment. The National Community of Pharmacists Association (NCPA) estimate that
over 20,000 pounds of unused and/or unwanted medications have been collected at 1,600
participating pharmacies that have collection centers across the country (NCPA, 2016).
The “Yellow Jug Old Drugs,” program operated by the Great Lakes Clean Water
Organization, is another program in Michigan, Wisconsin, Illinois, Indiana and it’s
expanding to Ohio. Jugs are located in pharmacies where users can drop their unused
medications for free. In Wisconsin, there are about 80 permanent collection points at police
stations throughout the state, along with one-day collection events. Minnesota has created
medicine collection events called “Medicine Cabinet Clean-Out Days” through the
Western Lake Superior Sanitation Department. The Illinois-Indiana Sea Grant (IISG) has
contributed to the implementation of take-back activities around the Great Lakes, with
concentration in Indiana and Illinois and a few activities in Michigan and Wisconsin. The
program started in 2008 and included both single day programs and/or permanent locations.
There are currently 39 programs operating in the Great Lakes region in addition to a
national program Prescription Pill Drug Disposal Program (P2D2) in 54 counties in Illinois.
An important component of the take-back programs is to communicate the
environmental impacts of pharmaceutical waste to consumers as well as to increase
consumer awareness of the problem. Increased consumer awareness can reduce the risks
of accidental poisoning and drive behavioral change towards better disposal practices.

4
Several studies have provided useful information regarding disposal practices, however the
results have very specific regional or local applications. A study in Santa Barbara county
in California found that consumers are willing to pay a $1.53 surcharge per prescription to
support the establishment of a pharmaceutical disposal program (Kotchen, et al., 2009).
The study also reported that willingness to pay varied with socioeconomic characteristic.
Additional data is needed to better understand the benefits of these programs. This study
analyzes household participation and willingness to pay for a pharmaceuticals disposal
program in the Great Lakes region.

1.2

Problem Statement

A number of unwanted and unused medicine collection programs have been
established throughout the Great Lakes region. These programs provide economic benefits
to society by properly disposing unwanted household pharmaceuticals, reducing
environmental pollution in water sources, and preventing adverse effects to organisms in
the different ecosystems. Additionally, economic benefits arise from averting public health
issues related to accidental poisoning and prescription medication abuse. There is no direct
relationship between these positive impacts and the corresponding monetary value since
these programs are a public good. Available literature suggests that it is very difficult to
establish a correlation between the medicines collected and the reduction in pollution in
each location given limited market economic data. Thus, to estimate the value of disposal
programs established in the Great Lakes Region, a non-market valuation model needs to
be employed. This research adopted multiple approaches to estimate the annual benefits of
collection programs.
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1.3

Overall Objectives

The overall objective of this research is to value medicine take-back programs in
the Great Lakes region to better inform program providers, researchers, policymakers,
advocates and other interested parties. The specific objectives are to:
1. Analyze the individual willingness to participate in a medicine take-back program.
2. Estimate the value of medicine take-back programs in the Great Lakes region using
willingness to pay for such programs.

1.4

General Hypothesis Statements

The hypotheses for the respective objectives are:
1. An individual that has had unwanted pharmaceuticals in their home over the past 12
months and has a higher environmental awareness is likely to participate in a medicine
take-back program.
2. An individual that has had unwanted pharmaceuticals in their home over the past 12
months and has a higher environmental awareness is willing to pay for a medicine takeback program.
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CHAPTER 2. BACKGROUND INFORMATION

This chapter provides an overview of pharmaceutical use and related environmental
and public issues. Some of the studies regarding the presence of medications in the
environment are discussed. The associated risks to both humans and wildlife are also
highlighted. Finally, some of the policy recommendations to reduce the impact of
unwanted and unused medications are mentioned. Special focus is centered on take-back
programs implemented at the national and international level.

2.1

Trends of Pharmaceutical Consumption

Pharmaceuticals, also referred to as medicines or drugs2 have been widely used
throughout history. Worldwide, it is estimated that about 4,000 different active
pharmaceutical ingredients (APIs) are administered with an estimated annual worldwide
consumption of 100,000 tones (IWW, 2014). Although pharmaceuticals are treated as
group of substances, they do not share any chemical, physical, structural or biological
factors. In fact, some of these compounds have other uses besides medicines (e.g.
nitroglycerine for vasodilation and dynamite). The only characteristic that brings this
varied group of chemical compounds together is their use. This means that any biologically
active substance has the potential to be a drug. Extensive research in pharmaceutical

Drugs can also refer to illegal substances. In the following paper, any reference to ‘drugs’ will not
consider this connotation.
2
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companies focuses on selecting the substances that produce the desired effect in animals
and/or humans, and with few or no adverse effects. Thus, from a risk-management
approach, pharmaceuticals go through a very specific assessment to ensure overall human
health and wellbeing. However, from an environmental risk assessment perspective, they
are no different from other chemicals. In general, they do not pose any more risks than
other biologically active components that have resulted from advances in analytical
science. However, unlike other chemical components, they are not regulated by an
international agreement or arrangement for their potential adverse effects. It is important
to bear in mind that because of their increasing use and potential benefits to society, the
risk/benefit calculations may differ significantly from other substances (Hester and
Harrison, 2015).
The most consumed prescription drugs are anti-hypertensives and analgesics,
followed by psychoactive products, anti-cholesterol agents, diabetes drugs and antibiotics
(NCHS, 2014). According to the World Health Organization (WHO), the U.S. is the leader
in total pharmaceutical expenditure and consumption, accounting for 32% of the world
spending and 55% of the total consumption (WHO, 2011). From 2010-2011, the estimated
U.S. national expenditure on overall prescriptions was $773 per capita. Consumption is
projected to continue growing for the upcoming years as a result of new drugs, expanding
population, aging population, and expiration of patents that result in more accessible
generic medications (HCCI, 2014). Pharmaceuticals also play an important role in the U.S.
national health care system, accounting for approximately 11% of overall health care
expenditures in 2013. From 2009-2012, 48.7% of the population used at least one
prescription drug within a 30-day period, while 21.8% had used three or more. Women,
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older adults and white persons are more likely to consume at least one prescription a day
(NCHS, 2014). The increasing consumption of prescription medicines presents challenges
associated with the excretion of these pharmaceuticals and the disposal of unused
medications into the environment.

2.2

Pharmaceuticals in the Environment

Drug residues have been increasingly found in the environment including rivers,
lakes, groundwater, and in lower levels in drinking water, soil, sediments, and manure
(Benotti, et al., 2009, Blair, et al., 2013, Cargouet, et al., 2004, Hughes, et al., 2012, Kolpin,
et al., 2002, Li, et al., 2010, Wu, et al., 2009). A 2014 global review of pharmaceutical
persistence in the environment found that, of the 713 pharmaceuticals tested, 631 were
above their detection limits in 71 different countries across the world (Hughes, et al., 2012,
IWW, 2014). The global occurrence is illustrated in Figure 2.1. This is probably an
incomplete picture of the problem, because there are no detection methods for all of the
thousands of pharmaceuticals in use around the world, and the analytical methods are not
standardized internationally, so detection limits may vary.
Some of the pharmaceutical substances that have been found include antibiotics,
analgesics, lipid-lowering drugs, beta-blockers, x-ray contrast media, and synthetic
estrogens. The average concentration detected in surface waters is 0.043 μg/L, with
individual APIs ranging from traces to 1 μg/L concentrations (Hughes, et al., 2012). Higher
concentrations may be found in highly populated areas or areas with high sewage effluents.
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Figure 2.1: Global Occurrence of Pharmaceuticals Detected in Surface Water,
Groundwater, Tap Water, and/or Drinking Water. (Source: IWW, 2014)

A number of drugs have been detected in the surface, shores, harbor, tributary rivers
and sediments of the Great Lakes. Some examples of the 39 drugs found include
metmorfin, caffeine, sulfamethoxazole, triclosan, carbamazepine, trimethoprim, naproxen,
ibuprofen, gemfibrozil (Blair, et al., 2013, Li, et al., 2010, Metcalfe, et al., 2003, Wu, et
al., 2009). Out of these 39 compounds, 14 were detected in Lake Michigan at high or
medium risk levels near waste water treatment plant (WWTP) effluent areas. Some
compounds dropped below the threshold levels to medium or low risk levels 2 miles away
from the shore due to the dilution effect. Yet, this was not the case for all the chemicals
(Blair, et al., 2013). As the biggest source of freshwater in North America, the potential
environmental effects in Lake Michigan are concerning.
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Figure 2.2: Main Emission Pathways of Human and Veterinary Pharmaceuticals Entering
the Environment. (Source: IWW, 2014)

But how do pharmaceuticals end in our water supply and other ecosystems? The
main sources and pathways through which medicines enter the environment are generally
well identified. Figure 2.2 summarizes the main emissions pathways through which APIs
can reach the different ecosystems. The left side of the diagram illustrates the main sources
which include: the pharmaceuticals industry, hospitals and elderly care facilities, final
consumers and animal husbandry and aquaculture.
The first pathway is through metabolic excretion from patients that end in the
wastewater and hospital effluents. The APIs are excreted either as metabolized substances,
or as unchanged active forms. A second pathway is from the industrial setting, where
residues from the process end up either in the wastewater or waste. A third pathway is
through excretion from animals which results as metabolites in manure and/or sludge.

12
Pharmaceuticals are also released into the soil when manure from animals treated with
veterinary drugs is used as fertilizer. A fourth pathway is the improper disposal of unused
medications through sinks and toilets that end in the sewage system. Medications are also
improperly disposed through the garbage, where leakage in the landfills might result in
APIs also entering the groundwater supply. Eventually, the APIs may accumulate in the
soil or drain into the groundwater.
Wastewaters are treated in a WWTP before being discharged to a body of water.
The problem with the compounds in medications is that conventional sewage treatment
facilities, including activated sludge processes, are not equipped to degrade every type of
medicinal substances. Studies suggest removal efficiencies at WWTP depend on the
individual pharmaceutical and technology, ranging from 20% to 80% (Gibs, et al., 2007,
Jelic, et al., 2011, Stackelberg, et al., 2007). Thus, a percentage of the medications that
reach the municipal sewage are released into the surface and groundwater sources either in
their original form or some kind of transformed chemical.
The biggest contribution with about 90% of the number of APIs in the environment
comes from residues excreted from patients, while the discharges from the pharmaceutical
industry account for only a small percentage (Hester and Harrison, 2015). The emissions
from the first source are usually widespread but at extremely low levels. Studies that have
evaluated the impact of discharges via excretion have found no evidence of any acute
effects related with the trace levels of medication attributed to this pathway. Manufacturing
discharges need to be regulated to avoid high concentrations in localized areas. In the U.S.,
monitoring and effluent standards result in a very small contribution to medicines in the
water system from the pharmacy production. Although the extent at which unwanted
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medications are disposed improperly into the sewage system is not known (estimated
between 5-10%), it is recognized that it has a significant impact on the load and
concentration of the effluent (Hester and Harrison, 2015).
To estimate the real effect of unwanted medications improperly disposed into the
environment, an estimation of the percentage of consumption from total sales for each
individual pharmaceutical and the disposal source would be necessary. Thus, a great level
of uncertainty exists in the estimations. Estimations from the European Union (E.U.) and
the U.S. regarding unused prescriptions and disposal practices have been able to shed some
light into this problem.
Unwanted medications in the E.U. have been estimated to represent 3 to 8% of total
sales (Hester and Harrison, 2015). In the U.S., estimates by the Pharmaceutical Research
and Manufacturers of America (PhRMA) of unused medications purchased by consumers
are at least 3%, equivalent to 2.8 million pounds, and 7%, 1.5 million pounds, from patients
in long-term facilities (PhRMA, 2011). Results from prescription adherence surveys
suggest that these percentages might by underestimating the unused amounts of medicines
in the country and amounts could actually represent 67% of total prescription medication
purchased (Law, et al., 2015).
The most common reasons for accumulation of unwanted and unused medications
in households are side effects to the medications, not adhering to the prescribed timeline
of the medical prescription, forgetfulness, over-prescription by physicians, automatic
refills, death of patient, and easy access to over the counter medications (Hester and
Harrison, 2015, Law, et al., 2015). The most common unused medications in Europe are
those related with cardiovascular diseases, asthma, nervous system and gastro-intestinal
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tract (Roig, 2010), while in the U.S., medicines related to chronic conditions such as
hypertension, diabetes, cholesterol and heart disease, pain medication and mental health
problems are the most commonly reported (Law, et al., 2015).
Medicine disposal behavior has been studied by several authors. In the U.S., the
most common disposal method for leftover medications is the garbage, followed by
flushing down the toiler or sink (Kotchen, et al., 2009, Kuspis and Krenzelok, 1996, Law,
et al., 2015, Musson, et al., 2007). Only an estimate between 10-15% of people with
medicines in their home dispose of them at a medicine collection center (Glassmeyer, et
al., 2009, Thach, et al., 2013). Individuals that are more aware of the environmental risk of
improperly disposing medicines are more likely to return their medications to a collection
center (Blom, et al., 1996, Kotchen, et al., 2009, Persson, et al., 2009, Tong, et al., 2011).
Once in the environment, living organisms are exposed to pharmaceutical
substances. Given that these metabolites may still contain APIs, they are potentially
harmful to the species of each ecosystem. The vast majority of drugs have not been
associated with a significant risk from chronic exposure to the concentrations in the
environment, but some drugs may still have the potential to affect wildlife or people (Hester
and Harrison, 2015). There is some evidence about the effects on metabolism regulation,
reproduction and development, and signal transmission disruption between cells of some
APIs, even at very low concentrations (Andersen, et al., 2003, Langston, et al., 2007, Swan,
et al., 2006). Links between pharmaceutical exposure and harmful effects have been
established in a limited number of different cases (Caldwell, et al., 2008, Hinck, et al.,
2008, Vajda, et al., 2008). These are summarized in Figure 2.3.
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Figure 2.3: Selected Examples of Adverse Effects of Pharmaceuticals and Non-Target
Organisms. (Source: IWW, 2014)

Ethinyl Estradiol (EE2), an active ingredient commonly used in contraceptive pills
and patches and as a medicine for breast cancer, prostate cancer, hypogonadism and
menopause has been detected since the late 1970’s in surface waters all over the world
(Andersen, et al., 2003, Caldwell, et al., 2008). EE2 is designed to mimic pretty closely its
natural analogue, while being more resistant to degradation in the human body, resulting
in a xeno-estrogen of high environmental concern. The median detection levels in lakes
across the United States are 0.13 ng/L (Kolpin, et al., 2002). It has been shown that even
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at low concentrations it has negative effects for reproduction and development in wildlife
given its persistence and high endocrine disruption potency (Andersen, et al., 2003,
Cargouet, et al., 2004, De Mes, et al., 2005, Langston, et al., 2007, Xu, et al., 2010). A
well-known case is the feminization of male fish. This effect is a consequence of exposure
to estrogens in the environment that can either trigger the expression of the VTG gene or
bind with receptors in the pituitary and/or hypothalamus, interfering with the natural
feedback mechanism of the endocrine system. Female fish can also suffer reproduction
disruptions that result in smaller eggs or inhibition of ovulation. The risk of these
reproduction and development disorders is the sustainability of fish population and the
adverse impacts this would have in other wildlife species.
Diclofenac is a non-steroid anti-inflammatory drug that was widely used for pain
relief in cattle prior to their deaths in the Indian Sub-continent. From 1996 and 2007,
millions of vultures would feast on the dead cattle carcasses, consuming the diclofenac
residues (Swan, et al., 2006). These birds, and the Gyps species (Gyps bengalensis) in
particular, have proven to be very sensitive to diclofenac, developing lethal gout in liver
and tissue, and kidney failure even when consuming very low doses of the drug (Oaks, et
al., 2004, Swan, et al., 2006). An estimate ranging from 10 to 40 million vultures died as a
result of exposure and 3 different species are critically endangered in Asia (Green, et al.,
2004). Veterinary diclofenac is now banned in India, Pakistan, and Nepal, yet this has not
resulted in full recovery of the vulture populations (IWW, 2014).
Due to the low concentrations of APIs found in the environment and the limitation
of reliable methods to monitor pharmaceutical residues in the environment, adverse effects
in the different ecosystems can be very difficult to determine. Furthermore, most of the
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affected organisms that live in the water are rarely observed in a day to day basis. Thus,
unless researchers are specifically assessing a species, any mild effect will most likely go
unnoticed. Consequently, stakeholders are concerned about the potential effects
pharmaceuticals may have on wildlife, particularly the long-term chronic effects that result
from bioaccumulation.

2.2.1

Pharmaceuticals in Drinking Water

Pharmaceuticals have also been found in the drinking water supply. Unlike surface
and groundwater, the concentrations found in human water supply is 100-fold below the
minimum therapeutic dose of 0.05 μg/L (Jelić, et al., 2012, WHO, 2012). The presence and
concentration of specific pharmaceuticals in drinking water varies from place to place,
depending on the primary pathway and total influents, dilution, natural attenuation and the
wastewater treatment technology employed. An analysis of 19 drinking water utilities in
2006 and 2007 in the U.S. found consistent traces of atenolol, carbamazepine, estrone,
gemfibrozil, meprobamate, naproxen, phenytoin, sulfamethoxazole, and trimethoprim in
source waters (Benotti, et al., 2009). Only meprobamate and phenytoin were detected in
finished water distribution systems. Median concentrations of all these APIs were
consistent with the world average concentrations, considerably below the therapeutic dose
(WHO, 2012).
An important finding of a study of pharmaceuticals in U.S. drinking water was that
the most prescribed pharmaceuticals were not detected in the drinking water supply, while
the 3 most detected drugs in source water were not even in the top 200 prescribed
pharmaceuticals (Benotti, et al., 2009). This discovery suggests prescription information is
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a poor proxy to medicine concentrations in water. For a more accurate measure, dosage,
pharmacokinetics, wastewater treatment technology and efficiency and environmental fate
need to be considered.
The World Health Organization suggests that due to this safety margin, it is very
unlikely humans will suffer any consequence from the current trace exposure (WHO,
2012). Nevertheless, potential effects in the future as a result of chronic exposure to trace
contaminants are a latent concern. The increase of water demand could potentially lead to
greater incidence of indirect and direct water reuse, and this could result in an increased
exposure to higher concentrations (Jones, et al., 2005).
Unfortunately, there is no information regarding the assessment of risks to human
health from long term exposure to low concentrations of medicines in drinking water, or
the possible combined effects from a mixture of APIs. There is a need to close the
knowledge gap regarding long-term, low level exposure (Jelić, et al., 2012, WHO, 2012).
Studies on the impact in more sensitive subpopulations such as children, pregnant women,
immune compromised individuals, and allergic people are another area of opportunity.
Evidence suggests that implementing additional specialized and costly drinking
water systems would not be efficient. No adverse effects to human health have been
documented so far, thus the health benefits would be limited. Preventing or reducing initial
concentration of pharmaceuticals in water sources should be sufficient to minimize the risk
of exposure. Specific action may be considered for localized areas where higher APIs
concentration has been detected and/or the influent discharge is significant and close to
important water sources.
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2.3

Public Health Issues

All prescription medications represent an incurred expense. In some cases, the
economic investment may be considerable. Thus, disposing of these medications may
represent money thrown away. Some consumers prefer to keep the medicines in their house
in case it is ever needed again or to give away to someone else that might need them. Both
of these behaviors represent other potential risks that arise with unused and unwanted
drugs.
Pharmaceuticals are considered the most common poison exposure in the country
(Mowry, et al., 2015). Accumulated medications in the house can increase the risk of
accidental poisoning of children and pets. Children often like to explore their surroundings.
If not properly stored, medicines around the home can be accidentally ingested. In 2003,
78,000 children under the age of five were treated for accidental poisoning of prescription
medications in the U.S. (CPSC, 2005). According to a study from the Cincinnati Children’s
Hospital, 12% of the cases of children poisoning with both prescription and over-thecounter medications required admission to the hospital and 4% of the cases resulted in
injuries. Accidental drug poisoning among children increased 22% from 2001 to 2008 with
only 5% of the cases related to dosing errors and 95% attributable to unintentional
consumption (Bond, et al., 2012).
Drug sharing with family and/or friends in the U.S. is illegal. Consumers might
engage in this practice with the purpose of reducing the cost of prescription for someone
else. The problem is that the purity of the medication cannot be assured. In cases where
medications haven’t actually been prescribed to the individual, drug sharing is equivalent
to self-medication. The risk is the potential side effects as a reaction to other medications
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the person is taking and/or particular individual characteristics (e.g. allergies) (Glassmeyer,
et al., 2009). Furthermore, sharing medications with family and friends can contribute
directly to the abuse problem by providing an easy supply point.
The non-medical use of prescription drugs in the U.S. is a significant problem
nationally, especially among adolescents. According to the National Institute on Drug
Abuse, an estimated 52 million people have abused prescription drugs at least once, from
which 6 million reported abusing them over the previous month (NCHS, 2014). Similarly,
the Partnership Attitude Tracking Study found that 24% of teenagers had misused or
abused prescriptions at least once, accounting for the third most prevalent drug behavior
amongst this population group (Kids, 2014). Only marijuana and alcohol have a higher
prevalence. In the last decade, abuse has increased dramatically. For example, the two most
commonly abused substances, opioids hydrocodone and oxycodone, have increase by
170% and 450% respectively since 1994 (NIDA, 2005).
The main reason for abuse of prescription medications across all ages is the desire
to experience the side effects (i.e. “getting high”). Among teenagers, another common
reason is the misconception of enhancing brain activity to improve school performance
(Kids, 2014). Most teenagers that abuse prescriptions usually obtain the drugs either
through friends or relatives, or from their parent’s medicine cabinet.
According to the National Center for Health Statistics (NCHS), drug overdose
death rates have increased five-fold since 1980, becoming the leading cause of accidental
deaths in 29 states. In 2014, more than 1,700 young adults died from prescription drug
overdoses, higher than from any other drug (NCHS, 2014). The estimated cost to the nation

21
include lost productivity, medical costs and criminal justice costs, which amounts to $53.4
billion a year (NCHS, 2014).
2.4

Policy Recommendations

Pharmaceutical pollution is an emerging problem that needs to be addressed to
protect ecosystems and public health. The Strategic Approach to International Chemicals
Management (SAICM), a policy framework adopted by the International Conference on
Chemicals Management (ICCM) commissioned by the United Nations Development
Programme (UNDP), adopted environmentally persistent pharmaceutical pollutants as an
emerging policy issue in their last meeting in September 2015. The resolution
acknowledges that in order to prevent, reduce and manage this issue, a multi-sectoral,
multi-stakeholder approach is needed. Coordination between intergovernmental
organizations, national governments, pharmaceutical companies, health care professionals,
veterinarians, waste water treatment plants, health insurance, academia and end user would
be more successful in ensuring sustainable policies. Some of the risk mitigation proposals
include monitoring campaigns, increasing environmental awareness, improving sanitation
and sewage treatment plants, updating and implementing of environmental standards, and
proper disposal of unwanted/expired pharmaceuticals.
In the U.S., 3 different agencies regulate the manufacturing, collection, discharge
and disposal of medicines: the U.S. Environmental Protection Agency (EPA), the Federal
Drug Administration (FDA) and the Drug Enforcement Agency (DEA). Some of the
regulations enforced by these agencies to address environmental and public health issues
related with pharmaceuticals are:
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Under the Federal Food, Drug and Cosmetics Act of 1980 (FFDCA), the FDA
is responsible of requesting and evaluating an environmental impact assessment
during the drug approval process. The National Environmental Protection Act
(NEPA) requires this assessment from all federal agencies that will decide upon
an action that may affect the human environment. The environmental
assessment evaluates potential environmental impacts from pharmaceutical
production. It should consider toxicity to organisms from the increased levels
of APIs in the environment resulting from the process and disposal of the
product. However, if the estimated concentration at the point of entry is below
1 part per billion, companies may qualify for a categorical exclusion.



The EPA, through the Safe Drinking Water Act (SDWA), governs public water
systems and establishes regulatory standards for over 100 chemical and
microbial contaminants in drinking water. In addition, the EPA has a list,
Contaminant Candidate List (CCL), which is continuously updated.



The Clean Water Act (CWA), also regulated by the EPA, helps prevent disposal
of pharmaceuticals from the industry to the public sewer system. However, even
though it regulates the wastewater treatment plants through the National
Pollutant Discharge Elimination System and could control the amount of
pharmaceuticals discharged by the plants, it usually does not monitor these
pollutants.



The DEA, under the Drug Abuse Prevention and Control Act, regulates the
disposal of pharmaceuticals. It does not regulate individual consumer disposal
as long as it is the prescription holder that disposes them. Returning controlled
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substances to pharmacies and distributors (except recall or dispensing errors) is
prohibited.
These regulations have proven to be insufficient in addressing the emerging
environmental problems. To properly inform policymakers on how to close the current
gaps in regulation, further research needs to be done to better understand and determine the
impact of pharmaceuticals in the environment.
Some of the concrete actions that could help mitigate the environmental and public
health issues of medicines by stakeholder, are:
1) Pharmaceutical industries: Pharmaceutical research and development to produce
drugs with non-persistent APIs after excretion and optimization of processes to
reduce biologically active waste (IWW, 2014, PSI, 2012, NRDC, 2009).
2) Government agencies: Tighter regulation regarding environmental impacts
through environmental assessments prior to granting approvals for production
and evaluation of APIs in sewage systems. Revision of current regulations may
also contribute to the reduction of medicines in the aquatic environment (PSI,
2012, NRDC, 2009).
3) WWTP: Improve removal in WWTP plants by using innovative processes.
Accurate data of concentrations of pharmaceutical residues in these plants
requires the development and standardization of advanced methods for
monitoring pharmaceuticals in different environments (IWW, 2014, PSI, 2012).
4) Researchers: Close the knowledge gap regarding the environmental and health
impact of persistent pharmaceuticals in ecosystems and drinking water. Some of
the research areas in need are: i) Volume and type of medications excreted and
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disposed; ii) Volume and magnitude of specific APIs in the environment; iii)
Contribution of environmental pollution from each source (human excretion,
industrial, animals and improper disposal); iv) types of persistent
pharmaceuticals in the environment and potential effects in ecosystems and
human health (IWW, 2014, PSI, 2012) .
5) Consumers: Disposal of unused and unwanted medications following best
management practices (IWW, 2014, PSI, 2012, NRDC, 2009).
6) Health providers and pharmacies: Reduce unnecessary pharmaceutical use by
decreasing over-prescription of healthcare providers, optimize pharmacy
processes (e.g. auto-refills, prescription plans), limit pharmaceutical marketing
campaigns, and awareness campaigns to reduce the overuse of antibiotics and
over-the-counter medications. (PSI, 2012, NRDC, 2009).
From all the policy proposals, the most important among the general population is
the proper disposal of medications. Improperly disposed medications are an easily
preventable source of contamination (IWW, 2014). The establishment and promotion of
take-back schemes for collection and disposal of unwanted and/or expired medications has
increased worldwide. The objective of these programs is to reduce the number of
pharmaceuticals that enter the environment by providing secure collection points and more
environmentally friendly destruction. Besides the disposal service, most programs focus
on increasing awareness of the risks of improper disposal. Another advantage of these
programs is the information that could be collected to have a better understanding of why
medications have accumulated. This information may be useful in the future to ensure a
more efficient supply chain. Existing programs vary significantly. Collection schemes can
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be one-day events, permanent drop-off sites in pharmacies, hospital center or police
departments, and mail-back programs.
In the European Union, take-back medicine schemes have been required by the
medicinal legislation since 2004 through the Directive 2004/27/EC. Out of 27 Member
States, 16 had recollection programs for unused and unwanted pharmaceuticals in 2013.
More than half are operated by the pharmaceutical industry or in collaboration with the
industry, and the remaining are paid by the local governments. The effectiveness of these
programs is yet to be evaluated.
In Canada, pharmaceutical companies have implemented a very successful drug
collection program in British Columbia since 1996. The British Columbia Medications
Return Program allows consumers to return medications free of charge in approximately
95% of pharmacies in the province. In 2011, 152,216 pounds of medicines were collected.
Some of the success factors have been the simple design and low cost of the program,
outreach to pharmacy certification boards and support of participating pharmacies
(BCMRP, 2014). Unlike the U.S., Canada does not have strict laws regulating custody of
controlled substances, facilitating the creation and support of similar projects.
Numerous states and counties across the U.S. have established pharmaceutical takeback programs, including permanent drop-off sites, single day collection events, and mailback programs. Clark County, Washington has had an unwanted medication take-back
program since 2003 (Clark County, 2016). Residents can drop-off their medications at no
charge at one of the 47 participating pharmacies. When pharmacies have filled the
containers, they ship them to the county’s hazardous waste contractor for incineration with
charge to the county. The solid waste managers of La Crosse County, Wisconsin developed
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a medicine disposal center for households. Residents from this county can drop-off all
household medicines for free, while residents from other counties and small businesses
(classified as very small quantity generators of hazardous waste) can participate and pay a
small fee. Medicines are discarded into a 55-gallon drum of solvent where they dissolve.
Once or twice a year, the containers are taken to incinerators. Estimated total annual costs
range from $12,000-$15,000, which are covered by the solid waste department’s regular
operating budget (La Crosse County, 2016).
In the Great Lakes region, a number of examples of pharmaceutical collection
programs include the Yellow Jug Old Drugs, operated by Great Lakes Clean Water
Organization, available in Michigan, Wisconsin, Illinois, Indiana and expanding to Ohio.
Jugs are located in pharmacies were users can drop their unused medications for free. In
Wisconsin, there are around 80 permanent collection points in police stations throughout
the state, along with one-day collection events (PSI, 2012). Minnesota has created medicine
collection events called “Medicine Cabinet Clean-Out Days through the Western Lake
Superior Sanitation Department. The Illinois-Indiana Sea Grant (IISG) has contributed to
the implementation of take-back schemes around the Great Lakes, concentrating in Indiana
and Illinois with a few in Michigan and Wisconsin. These 39 programs started operating
in 2008 and included both single day programs and/or permanent locations. Additionally,
in Illinois the national program Prescription Pill Drug Disposal Program (P2D2) is available
in 54 counties. This program started as a research project from High School Students in
Pontiac, Illinois (P2D2, 2016).
Despite the availability of take-back programs, a large percentage of the population
does not have sufficient access to secure medicine disposal centers. Estimation by the
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University of Wisconsin-Extension suggests only 2% of unused pharmaceuticals are
collected through these programs (PSI, 2012). As the public becomes more aware about
the risk of improperly disposing their medications, it is very likely the number of programs
across the country will continue to grow.
One of the problems with the establishment of these programs is that the Federal
Controlled Substance Act (CSA) did not allow the acceptance of controlled substances
from end-users, unless it was a law enforcement officer. A recent amendment has expanded
the options for the collection of controlled substances with the purpose of disposal (DEA,
2014). Yet, organizing and satisfying all legal requirements may impact the establishment
of new collection programs.
The vast majority of these programs are free to the users. Thus, program providers
incur costs associated with the program. Total annual costs vary significantly given the size
and type of program and extent of advertising. Cost ranges may vary from hundreds of
dollars to hundreds of thousands of dollars. Some of the costs may include: advertising,
security cameras, secure metal drop boxes, collection supplies, consolidation costs at
central collection site, warehousing, handling and transportation to disposal facilities,
disposal costs, personnel wages, and rent.
For more programs to be established, and a continuous support to the existing ones,
stakeholders (e.g. regulators, legislators, program providers, pharmaceutical industries, tax
payers) must be convinced that the societal benefits from these programs are higher than
the costs sustained.
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CHAPTER 3. ANAYSIS OF THE FACTORS THAT DETERMINE HOUSEHOLD
PARTICIPATION IN A MEDICINE TAKE-BACK PROGRAM

3.1

Introduction

Over the last decade, pharmaceutical residues have been increasingly found in
surface and groundwater in at least 71 countries around the world (Hughes, et al., 2012,
IWW, 2014). In Lake Michigan, 631 chemicals out of 713 that were tested, were found
above detection limits (Blair, et al., 2013). The pharmaceutical substances found include
antibiotics, analgesics, lipid-lowering drugs, beta-blockers, x-ray contrast media, and
synthetic estrogens. The introduction and accumulation of pharmaceutical residues in the
environment is a growing issue with implications for human health and ecosystems. Studies
have suggested that pharmaceutical compounds are potentially harmful to aquatic
organisms, affecting reproduction and development, even at very low concentrations
(Hinck, et al., 2008, Vajda, et al., 2008).
In September 2015, the Strategic Approach to International Chemicals
Management initiative of the United Nations Environment Programme, adopted
environmentally persistent pharmaceutical pollutants as an emerging policy issue (SAICM,
2015). Given the nature of the problem, a multi-sectoral, multi-stakeholder approach to
prevent, reduce and manage pharmaceuticals from entering the environment is needed. A
proposed activity to reduce the risk of pharmaceuticals is the establishment and promotion
of best management practices for disposal of unused and/or expired pharmaceuticals and
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raising awareness about the adverse effects of pharmaceuticals in the environment. This
study analyzes survey data and examines the factors that could influence the likelihood of
households participating in drug take-back programs. The information provided from this
study will help better target program advertising campaigns for both awareness and
participation.

3.1.1

Literature Review

Numerous studies have been published regarding human behavior and the
environment. This field of study, known as environmental psychology, has tried to explain
the complexity of direct and indirect environmental action trying to predict conservation
behaviors based on particular attitudes towards the environment. One of the most studied
issues is the difference between environmental awareness and pro-environmental behavior
and actions. Although several authors have designed theoretical frameworks to try and
explain the difference between environmental awareness and behavior, no convincing
conclusions have been reached yet (Kollmuss and Agyeman, 2002).
A common belief in the 1970’s was that increasing knowledge and awareness
through education and communication campaigns would lead to a positive change in
environmental behavior. Over the course of the decades, researchers have designed
different models to explain why this relationship is not observed when analyzing
environmental behavior. Factors included not only knowledge, but also the difference
between

indirect

learning

(e.g.

school,

advertising)

and

direct

experience,

sociodemographic components like social norms, cultural traditions and family customs
(Rajecki, 1982), beliefs of consequences and social pressure (Ajzen and Fishbein, 1980),
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the possibility to act, and economic constraints (Fietkau and Kessel, 1981, Hines, et al.,
1987). In practice, environmental behavior is so complex that it cannot be explained nor
represented by a single model.
As most researches have concluded, environmental knowledge and environmental
awareness can explain a small portion of environmental behavior, with at least 80%
explained by situational and other internal factors (Kollmuss and Agyeman, 2002).
Nonetheless, specific factors studied throughout the years have been found to exert either
positive or negative influence on pro-environmental behavior. Regarding demographic
factors, two variables have been found to be consistently correlated with environmental
concern. Regardless of what dependent variable measure is used, younger people are, in
general, more concerned about environmental quality (Klineberg, et al., 1998). Years of
education has also been found to have a positive correlation with pro-environmental
behavior. Better educated citizens will most likely have more knowledge about
environmental issues as well (Blocker and Eckberg, 1997, Klineberg, et al., 1998,
Kollmuss and Agyeman, 2002). In some cases, gender is included as one of the factors
which influences environmental attitude. Usually, women have been associated with a
higher environmental concern, given that they are more emotionally engaged than men,
show more concern towards environmental destruction, and are more willing to change
(Kollmuss and Agyeman, 2002, Kotchen, et al., 2009, Mohai, 1992, Stern, et al., 1993,
Torgler, et al., 2008). However, some studies have found mixed evidence (Blocker and
Eckberg, 1997, Klineberg, et al., 1998).
Economic factors have also been found to have an important effect on people’s
decisions towards the environment. The literature suggests a positive, although not
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conclusive, relationship between the value of environmental amenities and average income
(Ferreira and Moro, 2013, Klineberg, et al., 1998, McConnell, 1997).
The determinants of environmental concern vary significantly depending on the
assessment method, dependent variable used, and specific environmental behavior. A
generalized concern for the environment is not usually a determining factor for following
specific environmental behaviors. Individuals decide to express their concern in different
ways, thus explaining why some people are engaged in some environmental issues and
others are indifferent. The conservation literature suggests that researchers should focus
their studies on attitudes specific to the environmentally friendly behavior in question, and
not focus all their attention in general attitudes (Teisl and O'Brien, 2003). Attitudes are not
the ones that determine behavior directly, but they do influence actions.
Studies on pharmaceutical take-back programs have found that people that are more
aware of the consequences of improperly disposing pharmaceuticals in the environment
are more likely to take their unwanted and unused medications to a collection center (Blom,
et al., 1996, Kotchen, et al., 2009, Persson, et al., 2009, Tong, et al., 2011). The correlation
between age and pharmaceutical disposal practices is consistent with research about other
environmental behaviors, with younger adults more willing to pay for a medicine take-back
program. Other factors that have been found to influence the decision to participate in a
pharmaceutical collection program are gender (female) and political affiliation (democrat).
Qualitative choice models have commonly been used to forecast consumer demand
for goods that are both not available and available in the market (Beggs, et al., 1981, Jung,
1993) and also to assess consumer preferences and choices (Koop and Poirier, 1994). The
extension of these models to study environmental concern and different environmental
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behaviors has been common practices in the last couple of decades (Beggs, et al., 1981,
Bestard and Nadal, 2007, Jung, 1993, Saphores, et al., 2006, Sønderskov and Daugbjerg,
2011, Teisl and O'Brien, 2003, Vicente-Molina, et al., 2013). In this study, we use an
ordered probit model to assess the determinants of participation in a medicine take-back
program in the Great Lakes region.

3.1.2

Objectives

The specific objectives of this analysis are to:
a) Assess the determinants of participation in medicine collection programs in the Great
Lakes region.
b) Estimate the probability of likelihood of participation in a medicine collection
program in the Great Lakes region.

3.1.3

Hypothesis

The participation of a household in medicine collection programs will be
determined by their environmental awareness, presence of pharmaceuticals in their home,
and socioeconomic characteristics. Specifically:


Presence of unwanted pharmaceuticals in the household will have a positive
correlation with participation in the program.



Higher environmental awareness will have a positive correlation with participation
in the program.



Higher education will have a positive correlation with participation in the program.
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3.2

Data and Methods
3.2.1

Data

The data used in this model was gathered from an online survey administered
during the summer of 2015 in Indiana, Illinois, Michigan, Minnesota, Ohio and Wisconsin.
The survey was designed to learn about medicine disposal practices and willingness to
participate in a medicine take-back program. The target population included all individuals
at least 18 years of age from households living in these states. The total number of
respondents was 2,031, from which a total of 1,311 observations were considered for this
analysis. The additional 720 observations were excluded from the analysis due to missing
data. The complete survey can be found in Appendix A3.
The dependent variable in the model is the likelihood to participate in a medicine
take-back program. In the survey, participants were asked to indicate their likelihood to
participate in an unwanted pharmaceutical collection program in the next 12 months by
selecting an option from a 5-point scale; the answers included “Very likely”, “Somewhat
likely”, “Neither likely nor unlikely”, “Somewhat unlikely”, and “Very unlikely”. Twentyfour percent reported their participation in such programs to be either unlikely (16%) or
somewhat unlikely (8%) in the following 12 months. About 25% of the sample population
was uncertain, having reported they are neither likely nor unlikely to become participants.
About half of the survey responders stated to be somewhat likely (23%), and very likely
(25%) to use a pharmaceutical collection program in the coming year. For our analysis we
collapsed the responses into 3 categories, “Likely to participate”, “Neither likely nor

3

The survey can also be retrieved online at:
https://purdue.qualtrics.com/SE/?SID=SV_em724dM9PhaewHr
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unlikely to participate”, and “Unlikely to participate”. Fifty-six percent of the respondents
expressed their likelihood to participate in the future (like), 26% were neither likely nor
unlikely to participate (neutral), and 18% claimed it was unlikely they would participate
in a collection program (unlike). In Table 3.1 the likelihood of participation in a
pharmaceutical collection program by gender is summarized, where 58.97% of the male
and 54.31% of female respondents expressed their likelihood to participate in a program in
the coming year. Table 3.2 summarizes participation per state, where a higher percentage
of Illinois residents indicated they are likely to participate (61.97%), followed by Indiana
with 56.82% of sample residents.
Table 3.1: Likelihood of Participation in a Pharmaceutical Program per Gender.
Variable [%]

Unlikely

Neutral

Likely

Female

18.14

27.54

54.31

Male

17.69

23.34

58.97

Total [%]

18.00

26.24

55.76

Table 3.2: Likelihood of Participation in a Pharmaceutical Program per State.
Variable [%]

Unlikely

Neutral

Likely

IL

15.02

23.00

61.97

IN

15.15

28.03

56.82

MI

18.82

27.06

54.12

MN

25.97

32.47

41.56

OH

21.10

26.61

52.29

WI

20.45

28.03

51.52

Total [%]

18.00

26.24

55.76
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The independent variables considered for the model were grouped into socioeconomic variables (Dem), environmental practices of the household (Env), variables
related to unwanted pharmaceuticals (Phar), and location (Geo).
Environmental Practices (Env)
The environmental practices variables consist of environmental awareness and the
number of environmental programs the household is currently engaged in. These variables
were included to assess the portion of environmental behavior explained by environmental
awareness and environmental knowledge. As a proxy for environmental awareness, we
asked each subject how important environmental quality was for them in a 5-point scale.
Answer options included “Extremely important”, “Very important”, “Neither important
nor unimportant”, “Very unimportant”, and “Not important at all”. Responses where
consolidated into 3 categories: important (e.imp), neutral (e.ntrl) and unimportant
(e.unimp). Most people (84%) indicated environmental quality was important for them,
while 2% of respondent thought it was unimportant. About 14% of the individuals
expressed a neutral perception of environmental quality. Given the strong relation between
the medicine take-back programs with environmental concerns, we expect a positive effect
between environmental importance and participation in such programs.
In the survey, households were also asked about their participation in different
environmentally friendly programs including recycling, composting, water conservation,
energy conservation, or use of environmentally friendly products. In our model, we defined
the variable as the total number of programs each household currently participates in
(#envp). On average, households are involved in 3 programs. Of the sampled population,
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13.73% participates in one of these activities, 20.37% are engaged in two of these
programs, 27.61% in three programs, 28.99% in four programs, and 9.31% in all five
activities. Recycling and energy conservations are the most common practices, with 83.8%
and 80.5% respectively of the sample population engaged in these activities. Composting
is the least common environmental practice indicated; only 23.4% of the households are
doing it. This variable (#envp) is expected to be positive because the more environmentally
friendly programs households are enrolled in, we assume the more environmentally
conscious the household is, and thus we expect them to be more likely to participate in an
unwanted pharmaceutical collection program. Figure 3.1 show the proportion of the
number of environmental programs and type of programs, individuals are engaged in.

Figure 3.1: Number and Type of Environmental Programs Households are Engaged in.
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Unwanted Pharmaceuticals (Phar)
The unwanted pharmaceutical (Phar) variables were included to account for the
specific attitudes related to unwanted pharmaceutical collection programs. Participation is
associated with the presence of unused pharmaceuticals in the household. To account for
the effect of the presence of unwanted medicines in the household, 3 variables, summarized
in Table 3.3, were considered. The first variable related to households having had unwanted
drugs over the last 12 months (unmed). For this binary variable (Yes/No), 75% of
respondents answered positively, and 25% reported not having unwanted or unused
medications over the last year. Given that individuals with unwanted pharmaceuticals in
their home are the potential users of the program, a positive coefficient was expected. The
number of different prescriptions users are likely to dispose of (#Rx) were also included.
The mean number or prescriptions from the sample population was 2.27 prescriptions per
visit. Our assumption was that the more prescriptions a user is likely to drop off is
correlated with the number of prescriptions available in their households, and hence they
would obtain a higher utility from participating in medicine collection programs. It is also
anticipated that those people that have previously participated in a program would be more
likely to continue participating in the future if they considered the program valuable. To
assess this claim, we included a dummy variable for those that had previously participated
in a take-back program (part). Approximately 72% of the sample population had not
participated in a program before.
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Table 3.3: Summary of Unwanted Pharmaceutical (Phar) Variables.
Variable

Yes

No

Unmed [%]

75.36

24.64

Part [%]

27.61

72.39

Number Prescriptions (#Rx)

Mean

2.27

Socio-economic Variables (Dem)
To control for socio-economic differences and economic constraints, we included
average household income, education, age and gender into the model. The average annual
household income was separated into 5 categories. The categories were defined as: $0.00$30,000 (inc0), $30,001-$45,000 (inc30), $45,001-$60,000 (inc45), $60,001-$75,000
(inc60), and over $75,000 (inc75). The percentages of respondents per category are: 26%
(inc0), 17.2% (inc30), 16.6% (inc45), 13.3% (inc60) and 26.9% (inc75). The median
annual household income falls in the range of $45,001 - $60,000 USD, consistent with the
2014 Median Annual Household Income for the United States (U.S. Census Bureau, 2014).
The literature suggests a positive, although not conclusive, relationship between the value
of environmental amenities and average income (Ferreira and Moro, 2013, Klineberg, et
al., 1998, McConnell, 1997). Hence, it is expected that households in a higher income
groups are more likely to participate in a medicine collection program. In Table 3.4 the
composition of the dataset per income group and likelihood to participate are summarized.
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Table 3.4: Composition of Data Set per Income Group and Likelihood of Participation in
a Pharmaceutical Program.
Variable [%]

Unlikely

Neutral

Likely

Total [%]

Inc0

6.79

8.31

10.91

26.01

Inc30

3.66

5.03

8.54

17.24

Inc45

2.14

4.50

9.92

16.55

Inc60

1.68

2.36

9.23

13.27

Inc75

3.74

6.03

17.16

26.93

Total [%]

18.00

26.24

55.76

100.00

In addition to income, education can also be key in increasing environmental
awareness (Blocker and Eckberg, 1997, Klineberg, et al., 1998, Kollmuss and Agyeman,
2002). Consequently, a dummy variable for those participants who have at least a college
degree (edu) was included in the model. As shown in Table 3.5, 66% of the sample
population has obtained at least a college degree, while for 33%, their highest level of
completed education is high-school. In line with the literature, the assumption is that the
estimated parameter would have a positive sign.
Table 3.5: Composition of Data Set Given Education and Likelihood of Participation in a
Pharmaceutical Program.
Variable [%]

Unlikely

Neutral

Likely

Total [%]

Edu=0

7.32

10.30

15.41

33.03

Edu=1

10.68

15.94

40.35

66.97

Total [%]

18.00

26.24

55.76

100.00
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Previous studies have found a negative correlation between environmental
preferences and age (Klineberg, et al., 1998, Torgler, et al., 2008). Three age groups
ranging from 18-45 years old (age18), which compromise 52.6%, 46-65 years old (age46),
accounting for 32.4% and over 65 years old (age65) representing 15% of the sample
population, were included. The expectation is that younger adults are more likely to get rid
of their unwanted medications through a collection program. This variable is summarized
in Table 3.6.
The general consensus regarding gender is that women’s concern towards the
environment is stronger than men’s. This association has been found in several studies
(Kotchen, et al., 2009, Mohai, 1992, Stern, et al., 1993, Torgler, et al., 2008). However,
some studies have found mixed evidence (Blocker and Eckberg, 1997, Klineberg, et al.,
1998). To test this hypothesis, we included a dummy to assess the effect of gender in our
model (male), where the dummy was 1 if the respondent was a man. Thirty-one percent of
individuals are male, and 69% female. In Table 3.1, the likelihood of participation in a
pharmaceutical program for each gender is summarized, while Table 3.7 shows the
composition of the whole sample population by gender and likelihood to participate.
Table 3.6: Composition of Data Set Given Age and Likelihood of Participation in a
Pharmaceutical Program.
Variable [%]

Unlikely

Neutral

Likely

Total [%]

Age18

9.00

12.51

31.05

52.56

Age46

5.72

9.38

17.32

32.42

Age65

3.28

4.35

7.40

15.03

Total [%]

18.00

26.24

55.76

100.00
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Table 3.7: Composition of Data Set Given Gender and Likelihood of Participation in a
Pharmaceutical Program.
Variable [%]

Unlikely

Neutral

Likely

Total [%]

Female

12.51

18.99

37.45

68.95

Male

5.49

7.25

18.31

31.05

Total [%]

18.00

26.24

55.76

100.00

Location (Geo)
Finally, we included dummy variables for each of the states where the survey was
applied (IN, OH, WI, MI, IL, MN). The goal was to assess if there was any difference in the
likelihood to participate across geographical regions. The composition of the data per State
and indicated likelihood to participate is shown in Table 3.8.
Table 3.8: Composition of Data Set per State and Likelihood of Participation in a
Pharmaceutical Program.
Variable [%]

Unlikely

Neutral

Likely

Total [%]

IN

4.88

7.48

20.14

32.49

IL

3.05

5.64

11.44

20.14

MI

1.22

1.75

3.51

6.48

MN

1.53

1.91

2.36

5.80

OH

5.26

6.64

13.04

24.94

WI

2.06

2.82

5.26

10.14

Total [%]

18.00

26.24

55.76

100.00
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3.2.2

Methodology: Ordered Logit Model (OLM)

Ordinal variables in econometrics can be defined as those where a mapping from
an underlying, naturally preference scale is translated into an ordered observed outcome.
The order matters, which means they can be ranked, but the distance between one category
and the other is not known. Thus, when used as a dependent variable, they violate the
assumptions of the Linear Regression Models (e.g. OLS). McKelvey and Zavoina (1975)
and McCullagh (1980) introduced the ordinal regression model to social sciences for the
analysis of ordered, categorical, non-quantitative choices, outcomes and responses, where
the focus of the model was the analysis of the odds of choosing one response category
versus another.
The ordinal regression model is usually presented as a latent variable model, given
that it is an underlying random utility model. The structural model is defined as:
𝑦𝑖∗ = 𝒙𝒊 𝜷 + 𝜀𝑖 , 𝑖 = 1, … , 𝑛.

(4.1)

where 𝒙𝒊 is the vector set of independent variables, k. 𝒙𝒊 is assumed to be strictly
independent of the random error, ε, for every observation i, and 𝜷 is a vector of k
parameters to be estimated.
The independent variable measuring the random utility, 𝑦𝑖∗ , can be divided into J
ordinal categories, where the cut points 𝜏𝑚 to 𝜏𝐽 are estimated in the following way:
𝑦𝑖∗ =
=
=
=
=

0 if 𝜏𝑚−1 ≤ 𝑦𝑖∗ < 𝜏𝑚,
1 if 𝜏𝑚 ≤ 𝑦𝑖∗ < 𝜏𝑚+1,
2 if 𝜏𝑚+1 ≤ 𝑦𝑖∗ < 𝜏𝑚+2,
…
J if 𝜏𝐽−1 ≤ 𝑦𝑖∗ < 𝜏𝐽,

(4.2)
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The thresholds are an important element of the model since they divide the range of utility
into cells. An important assumption of the model is that these threshold values are the same
for everyone (Greene and Hensher, 2010).
For the purpose of our analysis, the empirical model for the variable groups was
defined as:
𝑦𝑖∗ = 𝑬𝒏𝒗𝒊 𝜷𝑬𝒏𝒗 + 𝑷𝒉𝒂𝒓𝒊 𝜷𝑷𝒉𝒂𝒓 + 𝑫𝒆𝒎𝒊 𝜷𝑫𝒆𝒎 + 𝑮𝒆𝒐𝒊 𝜷𝑮𝒆𝒐 + 𝜀𝑖 , 𝑖 = 1, … , 𝑛. (4.3)
where 𝑬𝒏𝒗𝒊 is the vector set of independent environmental variables including e.imp, e.ntrl
and #envp; 𝑷𝒉𝒂𝒓 is the vector set of pharmaceutical related variables including unmed,
part and #Rx; 𝑫𝒆𝒎 is the vector set of socioeconomic variables including inc30, inc45,
inc60, inc75, edu, age18, age46, and male; and 𝑮𝒆𝒐 is the vector of states IN, OH, WI,
MI, and IL. The dependent variable (𝑦𝑖∗ ) selected in the model was the naturally ordered
unobservable likelihood to participate. The choices from the surveyed individuals was
censored into three J categories: unlike, neutral, and like. Responses were censored into 3
categories to increase the number of observations for the lowest category (unlike) and
improve the asymptotic approximation without losing any information from the ordered
groups. Doing so does not affect the slope parameters, only the intercepts (Greenland,
1994, Peterson and Harrell, 1988). Some researchers have suggested a loss of efficiency
when collapsing categories in small sample, especially when converting into a
dichotomous choice (Murad, et al., 2003).
An important assumption that is made for the Ordered Regression Models is the
proportional odds assumption. This assumption implies that the slope coefficients are
identical across each regression. This means each probability curve for each level differs
only in being shifted to the left or right, meaning the 𝜷’s are the same for each threshold
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set of equations. Assuming the coefficients are equal, implies the estimated coefficients
should be close. If the parallel regression condition is not met, alternative models that do
not impose this constraint, such as the generalized ordered logit, should be considered. To
test this assumption in our model, we used a Wald test by Brant (1990), which tests the
parallel regression assumption for each dependent variable individually. The null
hypothesis implies that J-1 binary models can be estimated separately, and each would
have its own constant term, but the same slope vector. The hypotheses are defined as:
𝐻0 = 𝜷𝒒 − 𝜷𝟏 = 0, 𝑞 = 2, … , 𝐽 − 1.
𝐻𝑎 = 𝜷𝒒 − 𝜷𝟏 ≠ 0, 𝑞 = 2, … , 𝐽 − 1.

(4.4)

For our model, we used the “Brant” Stata command developed by Long & Freese
(2014). The resulting Chi-square from the Brant model for all variables was 15.08, with a
p> Chi-square of 0.72 with 19 degrees of freedom. The test result fails to reject the null
hypothesis, suggesting the ordered model specification is supported by the data. Detailed
results can be seen in Table 3.9.
The OLM is a maximum likelihood estimation, meaning the coefficient estimations
from the model are nonlinear. Unlike Ordinary Least Squares estimation, the model does
not directly describe the relationship between the dependent variables and the independent
variables, but instead describes the probabilities of outcomes. Therefore, the interpretation
of the coefficients differs from a traditional least square regression model and may become
a challenge when summarizing the effects of the independent variables. A common
approach is to estimate the probability of an observed outcome for a given value of x.
Pr(𝑦 = 𝑚|𝑥) = 𝑃𝑟(𝜏𝑚−1 ≤ 𝑦 ∗ < 𝜏𝑚, |𝑥)

(4.5)
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Table 3.9: Brant Test of Parallel Regression Assumption Results from Stata.
Variable

Chi2

p>chi2

All

15.08

0.724

e.ntrl

0.66

0.42

e.imp

0.02

0.88

#envp

0.04

0.85

part

1.74

0.19

unmed

0.12

0.73

#Rx

1.69

0.19

inc30

0.08

0.78

inc45

0.07

0.79

inc60

2.20

0.14

inc75

0.11

0.74

edu

0.30

0.58

age18

1.35

0.25

age46

0.00

1.00

male

0.39

0.53

IN

0.00

1.00

OH

0.80

0.37

WI

0.03

0.86

MI

0.34

0.56

IL

0.34

0.43

Vector

Env

Phar

Dem

Geo

4

A significant test statistic provides evidence that the parallel regression assumption has been violated.
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All estimations were done using STATA 13.1 and Long and Freese’s (2014) postestimation commands for ordinal outcomes.

3.3

Results and Discussion

The estimates for the Ordered Logit Model, summarized in Table 3.10, indicates:
𝑦𝑖∗ = 0.25𝑒. 𝑛𝑡𝑟𝑙 + 0.91𝑒. 𝑖𝑚𝑝 + 0.15#𝑒𝑛𝑣𝑝 + 1.78𝑝𝑎𝑟𝑡 + 0.55𝑢𝑛𝑚𝑒𝑑 + 0.34#𝑅𝑥 + 0.14𝑖𝑛𝑐30
+ 0.54𝑖𝑛𝑐45 + 0.89𝑖𝑛𝑐60 + 0.28𝑖𝑛𝑐75 + 0.15𝑒𝑑𝑢 + 0.27𝑎𝑔𝑒18 + 0.20𝑎𝑔𝑒46
+ 0.16𝑚𝑎𝑙𝑒 + 0.63𝐼𝑁 + 0.57𝑂𝐻 + 0.17𝑊𝐼 + 0.51𝑀𝐼 + 0.86𝐼𝐿+𝜀𝑖 .
∗
𝑦 = 0 𝑖𝑓 0 ≤ 𝑦 < 2.16,
𝑦 = 1 𝑖𝑓 2.16 ≤ 𝑦 ∗ < 3.78,

(4.6)

∗

𝑦 = 2 𝑖𝑓 3.78 ≥ 𝑦 .

These thresholds together with the predicted probabilities for the OLM model are
illustrated in Figure 3.2.
The model converges at -1,088.91, which represents the maximized value of the
log-likelihood function, and -1,291.912 for the log-likelihood for the intercept-only. A chisquare test of the log-likelihoods with 19 Degrees of Freedom indicates a rejection of the
hypothesis of no regression.
For logistic models, evaluating goodness of fit is not related with how well the
model predicts the outcome variable, but with the log-likelihood of the model. Yet, pseudo
R2s with a similar scale to R2, have been developed to assess the model fit. Just as OLS
regressions, a higher value indicates a better model fit, but they are not comparable one to
the other, or even between different pseudo R2s.

For this model, McFadden’s (1973)

pseudo R2 is 0.1571, which compares a model with just the intercept to a model with all
the parameters. McKelvey and Zavoina’s (1975) pseudo R2, which measures the ratio of
the regression variation to the total variation in the latent regression, is 0.385.
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Figure 3.2: Estimated Ordered Probit Model. (Adapted from Greene and Hensher, 2010)

The results from the analysis suggest likelihood of participation in a medicine takeback program is influenced by the number of environmental programs participants are
enrolled in (#envp), previous participation (part), presence of unwanted pharmaceuticals
in the house (unmed), the number of prescriptions likely to dispose of (#Rx), average
household income between $45,000-$75,000 (inc45), and being a resident from Illinois
(IL), at a statistically significant level of 1%. The importance towards the environment
(e.imp) and residents from Indiana (IN) and Ohio (OH) are significant at a 5% significance
level, while annual household income higher than $75,000 (inc75) is significant at a 10%
significance level. The sign or magnitude of the relationship cannot be determined from
the coefficients, since neither of them can be directly interpreted given that there is no
conditional mean function, 𝐸(𝑦|𝑥), to analyze (Greene and Hensher, 2010). Inference
about the threshold parameters do not provide any useful insight either. By definition, the
coefficients will be statistically significant, otherwise the underlying ordering assumption
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would not be valid, suggesting that the categories should be combined, changing the
specified model.
For the estimated model, the average partial effects (APEs) were calculated for the
purpose of interpreting the coefficients. The APEs evaluate the marginal effects for each
individual, and then uses the sample average of the computed effects. In non-linear models
with discrete variables, the average partial effects are of more interest than the partial
effects of the average because they are representative of the data (Papke and Wooldridge,
2008). The average partial effects are a function of all the parameters in the model, the data
and the variable of interest.
From Table 3.10, environmental importance has a positive effect on likelihood to
participate in a pharmaceutical collection program. The marginal effect is higher for those
that consider the environment important and stated being likely to participate in the future
(17%) that those that are neutral regarding their likelihood of participation in the future
(6%). Likewise, the number of environmental programs households are participating in has
a higher marginal effect (2.7%) on the likelihood to participate in a medicine take-back
program compared to being neutral (0.1%) or not likely to participate (1.8%). Among the
environmental factors, the importance that households attach to the environment has a
relatively higher influence on likelihood to participate than neutral environmental
importance and participation in other environmental programs. This difference might
indicate that participation in ecological programs can be linked with a particular
environmental issue the individual is concerned about, thus participating in a program
addressing a different environmental aspect (i.e. pharmaceutical contamination) is of no
interest to them, while environmental awareness is a more general behavior. Another
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plausible explanation for the difference in marginal effect is the difference between
observed and stated preference variables. The number of environmental programs a
household is engaged in, is an observed factor in the sense that these are activities they are
actually practicing. However, the importance an individual attributes to the environment is
a stated preference. It has been widely suggested in the literature that stated preference can
be overestimated when compared to observed behavior, since stating a preference will not
necessarily determine action. This may explain why although a high percentage of the
sample population with a high environmental awareness stated being likely to participate
in a medicine collection program in the future, only a small fraction of the population has
actually participated in the past.
Regarding the pharmaceutical variables, previous involvement in a program has the
highest positive effect on future participation. The marginal probability of participation is
about 33%. Although take-back medicine programs are free, users incur an opportunity
cost of learning how these programs work and where the disposal centers are located. Thus,
for individuals that have previously participated in such programs, the opportunity cost of
learning about these programs is lower than the perceived cost of environmental damage,
medicine abuse and/or accidental poisoning. Having unwanted medication at home would
result in about 10% increase in the probability of likelihood of participation in a medicine
collection program, while the effect of the number of prescriptions is 6%.
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Table 3.10: Marginal Effects of Likelihood to Participate
Marginal Effects
Variable
e.ntrl
Env

e.imp

Coefficient
Not Likely

Neutral

0.248

-0.030

-0.016

0.046

(0.427)

(0.052)

(0.027)

(0.079)

-0.111

-0.057

0.169

(0.051)

(0.027)

(0.077)

-0.018

-0.009

0.027

(0.006)

(0.003)

(0.010)

-0.218

-0.112

0.330

(0.022)

(0.010)

(0.027)

-0.068

-0.035

0.103

(0.016)

(0.009)

(0.025)

0.908**
(0.416)

#envp

0.146***
(0.053)

Part

1.776***
(0.169)

Phar

Unmed

0.554***
(0.135)

#Rx
inc30
inc45

0.342***

-0.042

-0.022

0.063

(0.045)

(0.006)

(0.003)

(0.008)

0.138

-0.017

-0.009

0.026

(0.175)

(0.021)

(0.011)

(0.033)

-0.067

-0.034

0.101

(0.022)

(0.012)

(0.034)

-0.109

-0.056

0.165

(0.026)

(0.013)

(0.038)

0.543***
(0.183)

inc60

0.887***
(0.208)

inc75
Dem

educ
age18
age46
Male
IN

-0.035

-0.018

0.053

(0.169)

0.283*

(0.021)

(0.011)

(0.031)

0.153

-0.019

-0.010

0.029

(0.126)

(0.015)

(0.008)

(0.023)

0.269

-0.033

-0.017

0.050

(0.174)

(0.021)

(0.011)

(0.032)

0.198

-0.024

-0.012

0.037

(0.182)

(0.022)

(0.012)

(0.034)

0.158

-0.019

-0.010

0.029

(0.132)

(0.016)

(0.008)

(0.024)

-0.077

-0.040

0.117

(0.032)

(0.017)

(0.049)

0.631**
(0.264)

OH
Geo

WI
MI
IL

-0.070

-0.036

0.106

(0.256)

0.572**

(0.031)

(0.016)

(0.047)

0.166

-0.020

-0.010

0.031

(0.293)

(0.036)

(0.019)

(0.054)

0.507

-0.062

-0.032

0.094

(0.328)

(0.040)

(0.021)

(0.061)

-0.106

-0.055

0.161

(0.031)

(0.016)

(0.047)

0.864***
(0.254)

cut1_cons

2.157***
(0.511)

cut2_cons

3.781***
(0.519)

N
* p<0.1; ** p<0.05; *** p<0.01

Likely

1,311
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All income levels have a positive correlation with a positive likelihood to
participate. The biggest effect though, is for those participants with a reported annual
household income of $60,000 to $75,000. They are 17% more likely to participate in a
take-back program while participants in the $45,000-$60,000 range are about 10% likely
to participate. Higher income has been associated with a positive correlation towards proenvironmental concern, which might explain the higher marginal effect at this level. Some
studies have suggested though, that at the upper end of the distribution, pro-environmental
behavior drops off. This might explain why the marginal effect in the highest income level
is 12% less than the $60,000-$75-000 income group.
Regarding location, the highest marginal effect for likelihood of participation is in
Illinois with 16.1%, followed by Indiana with 11% and Ohio with 10.6%. Illinois has the
highest population between the 6 states analyzed. Approximately 40% of the population
lives in Cook County, the second most populated in the U.S. It is geographically located
along the shores of Lake Michigan, which has received the most attention among the Great
Lakes regarding pharmaceutical pollution. Trace levels of APIs have also been found in
drinking water sources for the city of Chicago. Concerns about the implications for human
health among a densely populated area, and the economic losses from pollution to the lake
have prompted the state to actively work to address these issues since the early 2000’s.
Even though it failed to pass, in 2005-2006 a Bill to establish a pilot medical return
programs was debated. Since then, the Illinois Environmental Protection Agency has
launched an initiative in collaboration with public and private sector to promote
environmentally responsible disposal programs. The increased advertising of the concern
of pharmaceuticals in surface and drinking water, the education and awareness campaigns
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launched throughout the region, and the contribution between public and private sectors
could have resulted in a higher awareness of the issue among the population. Furthermore,
Illinois is a fairly liberal state. A study in California found that individuals with democrat
affiliation were 13% more likely to participate in a medicine take-back program (Kotchen,
et al., 2009). Thus, the political affiliation could also play a role in the higher marginal
effect compared to other states.
One of the suggested drivers of a marginal effect of 11% and 10% among Indiana
and Ohio residents is the drug abuse problems in these states. The main drivers of overdose
deaths in the U.S. since 2000 are opioids, which include prescription pain relievers. In
2014, Ohio was the 5th state in the country with the highest rate of death due to overdose,
while Indiana ranked 16th. From 2013 to 2014, Indiana had a statistically significant
increase of fatalities attributed to this cause. Indiana’s proximity to Illinois and
organizations such as IISG working in both states could also play an important role.
For the OLM, another useful way of interpreting the results and measuring the fit
of the model to the data is to assess the model’s ability to predict the outcomes. In Table
3.11, the sample data indicates 18% of the consumers are not likely to participate in a takeback medicine program, 26% are neutral, and 55.8% will likely participate. The model’s
predicted probabilities are very close to those observed for every category from the
estimation sample. Using the whole dataset (2,030 observations), the model’s forecasting
power is still good, with the predictions of each outcome falling within the standard
deviation.
Table 3.12 shows that the predicted probability of neutral participation remains
very close to the percentage of responses from the survey, with a variation of only -1.7%.
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Meanwhile, the model’s prediction for households being likely to participate is
overestimated by 7.7% and those not willing to participate underestimated by 6%. This is
probably driven by the difference between the survey sample and model sample
observations.
Table 3.11: Percentage of Likelihood to Participate and Predicted Probabilities
Calculated from OLM Sample.
Respondents [%]
Variable

Predicted probabilities

Observations
Mean

Mean

St Dev

Not Likely

1311

0.18

0.18

0.16

Neutral

1311

0.26

0.26

0.12

Likely

1311

0.56

0.56

0.25

Table 3.12: Percentage of Likelihood to Participate from Survey Sample
Variable

Observations

Mean

Not Likely

2031

0.24

Neutral

2031

0.28

Likely

2031

0.48

After calculating the predicted probabilities from the general model, we calculated
the individual predicted probabilities for both men and women from a nationally
representative sample: mean age of 38 years old, median income of $51,759 and without a
college degree. We also estimated the individual probabilities for the sample with the same
characteristics but with a college degree. The individual estimated probabilities are
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summarized in Table 3.13. It can be observed that the model predicts individuals age 1845 with annual household income from $45,000 - $60,000 are more likely than the rest of
the population to participate in a medicine program. In particular, an increase in education
increases the probability of likelihood of participation in both men and women by about
3.3% and 3.5%, respectively. These findings align with the suggestions in the literature
where more educated people are more likely to engage in pro-environmental behavior.
According to the model predictions, men in these age and income ranges, are also
more likely than women to participate in a collection program by 3.6% for those without a
college degree and 3.4% with a college degree. These findings contrast with previous
studies of general environmental awareness where women have been found to be more
likely to participate than men (Kollmuss and Agyeman, 2002, Kotchen, et al., 2009, Mohai,
1992, Stern, et al., 1993, Torgler, et al., 2008). Other studies assessing pro-environmental
behavior have found mixed evidence regarding the effect of gender (Blocker and Eckberg,
1997, Klineberg, et al., 1998). Blocker and Eckberg (1997) have suggested that higher
environmental concern of women does not translate into significant higher participation in
environmental actions than men.
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Table 3.13: Individual Predicted Probabilities for Nationally Representative Sample
Participation
Individual Characteristics
Not Likely

Neutral

Likely

Women age 18-45, annual income $45-$60 MUSD,
no college degree

0.10

0.26

0.63

Men age 18-45, annual income $45-$60 MUSD, no
college degree

0.09

0.24

0.67

Women age 18-45, annual income $45-$60 MUSD,
with college degree

0.09

0.24

0.67

Men age 18-45, annual income $45-$60 MUSD,
with college degree

0.08

0.22

0.70

From a policy perspective, policymakers can influence environmental concern
through different programs and education campaigns. However, they have little influence
on socio-demographic conditions in the short run. For this reason, the individual predicted
probabilities of likelihood of participation were calculated given the respondents’ concern
for the environment, and the number of environmental programs they are enrolled in. Both
Table 3.14 and Table 3.15 summarize the results. From Table 3.14, the predicted
probabilities indicate a high predicted probability of likelihood to participate in a medicine
collection program in the future, irrespective of environmental concern. Those that
consider the environment important have a higher predicted probability of likelihood to
participate (62.5%) compared to neutral (46.3%) and unimportant (40.2%). Given that the
predicted probability of possible participation estimated by the model increases as
individuals become more concerned for the environment, policymakers have an
opportunity to influence participation through environmental awareness interventions.

61
Table 3.14: Predicted Probabilities of Participation Given Environmental Concern
Participation
Environmental concern
Not Likely

Neutral

Likely

Important

0.11

0.27

0.63

Neutral

0.19

0.35

0.46

Unimportant

0.23

0.37

0.40

In Table 3.15, the predicted probabilities are calculated given the number of
environmental programs households are engaged in for only those users with neutral
concern for the environment. The results show that, the more programs a household
participates in, the more likely they will consider returning their medications through a
disposal program. For example, although a household is neutral regarding environmental
concern, the model predicts they are 71.2% more likely to participate in a medicine
collection program if they are already involved in 5 environmentally friendly programs.
Those engaged in 4 programs are 68% more likely and even those engaged in 1 program
are about 58% likely to participate in a medicine take-back program. This observation was
previously suggested by Teisl and O’Brien, who argued that if participating in more
environmental program has significant impacts on environmentally friendly behavior, then
policies and programs promoting these kind of activities as a whole should be considered
when discussing actions to promote environmental sustainability (Teisl and O'Brien, 2003).
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Table 3.15: Individual Predicted Probabilities Based on Participation in Environmental
Programs for Consumers with Neutral Environmental Concern
Participation in Environmentally Friendly
Programs

Outcome Category of
Participation
Not Likely

Neutral

Likely

One Program

0.13

0.30

0.58

Two Programs

0.11

0.28

0.61

Three Programs

0.10

0.26

0.65

Four Programs

0.09

0.24

0.68

Five Programs

0.07

0.22

0.71

3.4

Policy Implications and Conclusions

Unwanted and unused medications stored in households have been associated with
prescription abuse and accidental poisoning. The improper disposal of these substances has
also been linked with surface and ground water pollution that affects ecosystems; it may
also have an effect on humans through drinking water. Medicine take-back programs have
been created to mitigate these problems.
This study assessed the determinants of household participation in a pharmaceutical
collection program. The results show that presence and number of unwanted
pharmaceuticals in the household are important factors that influence participation. Income
is another factor that affects the household’s decision. The model indicated the highest
marginal effect for individuals with an annual household income of $60,000-$75,000. A
number of programs have targeted their advertisement campaigns to older sectors of the
population because of the higher incidence of prescriptions in this group. In contrast, the
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model suggests a higher marginal effect for young adults. These findings suggest that if
program providers target education and awareness campaigns at younger individuals as
well, household participation is likely to increase at a higher rate, all other things equal.
Another finding from the analysis is that environmental awareness does play a
major role in determining positive stated likelihood to participate in this environmentally
friendly practice. When estimating the predicted probabilities of participation for those that
consider themselves neutral regarding the environment and given the level of participation
in other environmental programs, the study suggests there is a positive correlation between
the probability of participation in a medicine collection program with the more
environmentally friendly programs the household is already engaged in. Policymakers and
program providers can utilize these findings by creating synergies with other
environmental programs and leverage on existence awareness campaigns.
The study results reflect a high level of participation in a drug collection program
over the coming 12 months. However, in practice only a small percentage of the population
has attended single day or permanent collection centers to dispose of their medications.
This difference in stated vs. observed preferences indicates results should be interpreted
with caution, bearing in mind the methodological limitation of the theoretical framework
to estimate reality.
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CHAPTER 4. WILLINGNESS TO PAY FOR AN UNWANTED MEDICINE
COLLECTION PROGRAM: A DOUBLE HURDLE APPORACH

4.1

Introduction

A number of states and counties across the U.S. have implemented medicine takeback programs to mitigate the environmental problems of improper pharmaceutical
disposal and public health risks of accumulation of medicines in households.
Pharmaceutical take-back programs have been established in different areas, including
permanent locations in police departments, pharmacies, hospitals and other health care
facilities, special single and multi-day collection events, and mail programs. Several
studies have examined the underlying reasons for pharmaceutical accumulation in
households, household pharmaceutical disposal practices, the perception among users and
non-users of pharmaceuticals programs, and the willingness to pay for collection programs.
However, only a limited number of studies have estimated the social benefits of such
programs, and there is no such study in the Great Lakes region. This research examines
unwanted medication collection programs in the Great Lakes region with the intent of
closing the knowledge gap and provides information on the program’s value to
policymakers, researchers and program providers.
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4.1.1

Literature Review

Pharmaceuticals have been used for thousands of years to treat illnesses and diseases.
The U.S. has the highest consumption and expenditure of these chemical components (WHO,
2012). Over the last two decades, stakeholders have wondered about the environmental effects
of medicines found in surface and groundwater. Some studies have found detrimental effects
in wildlife and ecosystem, even at very low concentrations (Hinck, et al., 2008, Vajda, et al.,
2008). Active pharmaceutical ingredients (APIs) enter the environment as a result of excretion
from humans, pets and livestock, waste waters from the pharmaceuticals industry, and
improper disposal of unused and unwanted prescriptions. Excretion is the most frequent
pathway, but in trace concentrations. Flushing medications down the toilet or sink results in
high levels of unaltered APIs entering the sewage system and eventually ending up in
groundwater. In addition to environmental pollution, unwanted and unused pharmaceutical
products at home present a risk for accidental poisoning of children and pets and drug abuse.
Prescription drug abuse is a serious public health issue in the country, being the most
commonly abused substance leading to death from overdose, even ahead of heroin (NCHS,
2014).

There are several studies on the underlying causes resulting from pharmaceuticals.
Some of the topics assessed include the reasons behind pharmaceutical accumulation. The
most common reported reasons include recovery from illness, side effects, forgetfulness,
death of the patient, automatic refills and over-prescription by physicians (Law, et al.,
2015, Ruhoy and Daughton, 2008, Seehusen and Edwards, 2006). The most common
disposal practice is the garbage, followed by flushing down the toilet and pouring down
the sink. An estimated 10-15% takes their medications to a collection center for proper
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disposal. It is more likely for individuals that are more environmentally conscious to follow
this behavior (Bound, et al., 2006, Glassmeyer, et al., 2009, Kotchen, et al., 2009, Kuspis
and Krenzelok, 1996, Musson, et al., 2007, Seehusen and Edwards, 2006, Thach, et al.,
2013).
Regarding pharmaceutical take-back programs, a few of the studies have looked at
the perception of these programs among users and non-users. Thach et al. (2013) suggest
both users and non-users view such programs as a potentially valuable service. About half
of the respondents expressed their willingness to pay on a per weight basis. Other studies
have evaluated participation rates and the most common medications returned in pilot
programs. (Lystlund, et al., 2014, Perry, et al., 2014). One study in California estimated
the mean willingness to pay for the establishment of a program in the county (Kotchen, et
al., 2009).
These studies have provided useful information that has helped to understand
behavior and practices towards prescriptions medications in the U.S. Program providers
and policymakers have been able to benefit from the research results to improve awareness
throughout the community and concentrate efforts on specific issues. However, it is not
possible to extrapolate the results and draw regional or national conclusions, since the
sample size for most of these studies is very small, and usually not random.
A number of states and counties across the U.S. have implemented programs to
mitigate the environmental problems and public health risks of pharmaceuticals. In the
Great Lakes region, some examples of these programs include the Yellow Jug Old Drugs
in Michigan, Wisconsin, Illinois and Indiana; Medicine Cabinet Clean-Out Days in
Minnesota; and other programs supported by the Illinois-Indiana Sea Grant in police
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departments mainly across Illinois and Indiana, as well as the Prescription Pill Drug
Disposal Program (P2D2). A common question among program providers and policymakers
is the estimated monetary value of the economic benefits provided to society by these
programs. To our knowledge only one study has estimated the mean willingness to pay
(WTP) for the implementation of a medicine take-back scheme in a community in Santa
Barbara, California.
The contingent valuation (CV) method (Mitchell and Carson, 1989) has been
commonly used to estimate the economic value of non-market goods. It is a methodology
used to estimate the monetary value of environmental services such as basic life support
functions of the ecosystems, wilderness experiences, appreciating wildlife, recreation in
lakes and rivers, and knowledge of a species existence. The two main fields of application
are the economic valuation of environmental projects to improve environmental quality
and to assess the damage from environmental deterioration. If the value of these activities
and positive externalities were assessed through their market value, most likely their
benefit would be zero. Not considering the non-use value would give wrong signals to
policymakers.
The CV method is based on asking people through a survey about their preferences
towards a specific good or service. To do so, the research needs to create, through a
questionnaire, a hypothetical market where the good or service in question can be traded.
The “contingent” component arises because the individuals are then asked to state their
preferences, contingent on that specific hypothetical market and the description of the
environmental service. The theory assumes that the stated willingness to pay or willingness
to accept (WTA), depending on the method employed, are related to the respondents’
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underlying preferences. Both concepts derive from the Hicksian welfare measure of
compensating variation and equivalent variation. Preferences are consistent with the utility
maximization principle.
The problem with CV and its major criticism is the fact that it is based on asking
people about their possible behavior, rather than observing their actual behavior, as
“revealed preference” methods do. Researchers argue that the stated preferences may
overestimate their real preferences. This is because the way individuals make a
hypothetical decision is fundamentally different from making an actual decision.
Furthermore, a number of biases can arise if there is a disconnection between the
hypothetical market the researcher intends to portray and the market the consumer bases
his answer on.
Stated preferences methods include WTP and WTA. Willingness to pay is the
maximum amount an individual is willing to sacrifice for a good or service they view
desirable or avoid something undesirable. In contrast, willingness to accept is the minimum
amount a person is willing to accept to let go of a good or give approval for a negative
externality (Boardman, et al., 2006). Even though in theory the valuation of a good should
be the same regardless of the method use, in practice this has not been the reality. WTA
have been found to significantly exceed WTP (Coombs, et al., 1967, DellaVigna, 2007,
Hammack and Brown, 1974, Hanemann, 1999, Kahneman, et al., 1990, Knetsch, 1990,
Lienhoop and MacMillan, 2007, Randall and Stoll, 1980). Several explanations have been
proposed, including the lack of income constraints, commitment costs, moral property
rights, and human psychology towards getting rid of a good versus receiving (Boyce, et al.,
1992, Hoffman and Spitzer, 1993, Kahneman, et al., 1991, Knetsch, 1995, Lin, et al., 2006).
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It is for this reason that WTP has been most widely used for the valuation of environmental
programs.
The use of a dichotomous format in CV was first incorporated by Bishop and
Heberlein (1979). The discrete choice attempts to identify if an individual’s underlying
value is higher or lower than the stated amount. The general structure for these surveys is
a take-it-or-leave-it offer, also known as the elicitation format. The bidding game follows
up on the response with either a higher or lower bid amount (depending on the first answer),
until their decision changes from yes to no (or no to yes). Similar formats include the spike
model and the one-and-one-half-bounded. The closed-ended format is preferred among a
number of researchers because of the simplification of the thinking process of respondents
(Mitchell and Carson, 1989). The mean value is estimated by comparing the bid amounts
and the respondent’s underlying value. Some of the discrete choice models that have been
employed include probit, binomial, multinomial, nested and mixed logit, and Tobit or
censored regression.
During the 90’s an interest in recycling as a way to reduce municipal solid waste
disposal led to a number of benefit-cost analysis to assess possible policy options. The
estimation of the benefits of the implementation of curbside recycling programs, drop-off,
recycling locations, automated systems, and electronic waste have all recurred to WTP as
a valuation method. All these studies used some kind of dichotomous-choice survey format
(Aadland and Caplan, 2003, Camacho-Cuena, et al., 2004, Jamelske and Kipperberg, 2006,
Lake, et al., 1996, Tiller, et al., 1997).
The cost of using dichotomous format in surveys is the loss of efficiency. The use
of an open-ended format allows for the collection of more information and obtains the
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respondent’s maximum WTP. However, a common problem when using and list of bids
and open-ended question is the frequency of zero WTP reported, resulting in observations
clustered around the zero value. This characteristic of the dataset requires a censored or
truncated econometric approach to avoid biases and inconsistent estimates of the
parameters (Tobin, 1958).
These models do not allow a variation in the factors affecting whether or not
respondents’ participant in the hypothetical market, versus the factors that affect the stated
amount that they are willing to pay. A double-hurdle by Cragg (1971) approach allows a
variable to be excluded from one of the two decision processes, and has been used to
estimate the mean WTP for different pro-environmental behaviors. These studies have
taken into consideration data clustering around zero WTP, and allowing for factors that
determine participation and consumption to vary (del Saz-Salazar and Rausell-Köster,
2008, Lera-López, et al., 2012, Martínez-Espiñeira, 2006, Moon, et al., 2002, Zorić and
Hrovatin, 2012).
Kotchen, et al. (2009) analyzed the willingness to pay for the establishment of a
pharmaceutical program in Santa Barbara, California. An assessment through contingent
valuation concluded individuals are willing to pay, on average, a premium of $1.53 on each
prescription bought to fund a pharmacy disposal program. The estimated total annual
benefit for the U.S. was $2.9 billion dollars. The problem of generalizing the findings from
this study to the Great Lakes region is the possible biases that could arise as the result of
the difference between the representative samples, the number of take-back programs
available in the region, the potential costs of environmental pollution in the surface waters,
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and the realistic realization of the hypothetical case scenario used for contingent valuation
in the region.
4.1.2

Objectives

The specific objectives of this study are to:
a) Analyze individual’s choice process with respect to willingness to pay for a
pharmaceutical take-back program in the Great Lakes region.
b) Assess the determinants of individual’s WTP for a medicine collection program.
c) Estimate the mean value of a pharmaceutical collection program in the Great Lakes
region.
4.1.3

Hypothesis

The WTP for a medicine collection program is a two-step decision program. First,
a decision is made if they are willing to pay for such a program. If they are willing to pay,
then the second decision is how much, either per prescription or per visit. The decision
process is influenced by the individual’s environmental awareness, presence of
pharmaceuticals in their home, and socioeconomic characteristics.


Presence of unwanted pharmaceuticals in the household over the past 12 months
has a positive correlation with WTP for a medicine take-back program.



Higher environmental awareness has a positive correlation with WTP for a
medicine take-back program.



Higher education will have a positive correlation with WTP for a take-back
medicine program.
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Individuals with a higher income are more willing to pay for a medicine take-back
program. The amount an individual is willing to pay for an unwanted
pharmaceutical program will be determined by their purchasing power.

4.2

Data and Methods
4.2.1

Data

To analyze the individual’s choice regarding their willingness to pay for medicine
take-back programs, the responses from an online 23-question survey was used. The survey
was designed to gather information regarding presence of unwanted pharmaceuticals
within the household, general medicine disposal practices, likelihood to participate in a
medication take-back program, willingness to pay for a medicine disposal program (per
prescription and per visit), importance of the environment, and a number of demographic
variables from individuals at least 18 years of age. The survey covered households living
in Indiana, Illinois, Michigan, Minnesota, Ohio and Wisconsin. The survey was
administered by Qualtrics during the summer of 2015. The complete survey instrument can
be found in Appendix A.
The sample population was randomly selected, and considered both current and
potential participants of take-back medication programs. A total of 2,443 people started the
survey. Out of this, 67 were younger than the target population, 15 lived outside the
delimited geographical area, and 330 did not complete the survey. This resulted in a total
number of respondents of 2,031, from which 378 had previously participated in a medicine
take-back program. For this analysis, 1284 observations were considered since 747
observations had missing data.
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The survey participants were asked to establish their willingness to pay per
prescription (WTPP) and willingness to pay per visit (WTPV). The contingent valuation
question was designed assuming a fee had to be paid to drop medications, based on either
the number of prescriptions or the number of visits. It is important to mention that currently,
all programs are free and there is no actual policy recommendation to charge a participation
fee. The hypothetical state was established in the following way:

“The presence of pharmaceuticals in surface waters is a growing concern. Let’s
suppose local authorities are to charge a fee for take-back pharmaceutical programs
at local permanent collection sites (e.g. pharmacies, hospitals, other health care
centers, police departments, and hazardous waste centers) to address this concern.”

Subsequently, respondents were asked about their willingness to participate,
average number of prescriptions likely to dispose-off, and WTP based on the number of
prescriptions and per visit. Given the limitations of the survey to ensure a response to these
questions, ranges were provided for respondents, instead of allowing for an open question.
The options provided for WTPP ranged from $0.00 to $3.00, with $1 dollar increments,
and $0.00 to $6.00 with $2 dollar increments for the per visit option. About 60 % of
respondents indicated they were not willing to pay to drop off their medications.
Approximately 20% expressed their willingness to pay up to $1.00 per prescription and
21% to pay up to $2.00 per visit to drop off unwanted pharmaceuticals. On the average,
8% said they would pay around $1.01-$2.00 per prescription, and 9% $2.01-$4.00 per visit.
Fewer people (7%) admitted to being willing to pay about $2.01-$3.00 per prescription and
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$4.01-$6.00 per visit. Only 4% expressed their willingness to pay more than $3.00 per
prescription, and 3% more than $6.00 per visit. Table 4.1 summarizes the percentage of
individual’s willingness to pay per prescription and Table 4.2 their willingness to pay per
visit. Consistent with economic theory, the trend is that at a higher price, consumers are
less willing to pay to take their unwanted medicines to a permanent collection center.
Table 4.1: Distribution of Responses for Willingness to Pay per Prescription
WTTP [USD]

Frequency [%]

$0.00

60.89

$0.01-$1.00

19.83

$1.01-$2.00

8.43

$2.01-$3.00

6.71

$3.01+

4.14

Table 4.2: Distribution of Responses for Willingness to Pay per Visit
WTTV [USD]

Frequency [%]

$0.00

59.64

$0.01-$2.00

21.23

$2.01-$4.00

9.21

$4.01-$6.00

7.26

$6.01+

2.65
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All respondents were also asked about their likelihood to participate in a take-back
medicine program in the future, before stating a hypothetical state regarding their
willingness to pay to participate in the program. This question helped us identify those
persons that consider the program valuable enough to participate, but were unwilling to
pay for it. Eighteen percent reported they were not likely to participate in such programs
in the following 12 months. About 26% of the sample population was uncertain, having
reported they are neither likely nor unlikely to become participants. About half (56%) of
the survey respondents indicated they were likely to use a pharmaceutical collection
program in the coming year. However, when asked about their willingness to participate in
the hypothetical scenario that charges a fee to use the program, only 36% responded they
were willing to participate, and 12% reported they were neither willing nor unwilling. Half
of the households (51%) were unwilling to drop off their medications in a permanent
location if a fee was implemented.
As shown in Table 4.3, 26.72 % of the sample population stated they are likely to
participate in a medicine collection program within the next month, and they would be
willing to participate even if a fee had to be paid for every prescription dropped-off or
every time they used the program. An estimate of 24% of individuals stated they would be
likely to dispose of their unwanted medications through a program, but when asked if they
would be willing to participate with a fee in place they said no. This observation suggests
there is a number of individuals that consider the benefit of the program is greater than the
opportunity cost of participating, as long as no other fees are in place.
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Table 4.3: Percentage of Likelihood of Participation and Willingness to Participate in a
Medicine Take-Back Program.
Variable [%]

Unlikely

Neutral

Likely

Total

Unwilling

12.97

14.69

23.52

51.17

Neutral

2.34

4.61

5.47

12.42

Willing

2.81

6.88

26.72

36.41

18.13

26.17

55.70

100.00

Total

The variables that were considered relevant as the determinants of WTP included
environmental practices of the household (Env), pharmaceutical related variables (Phar),
and demographic variables (Dem).
Environmental Practices (Env)
Pharmaceutical collection programs have a positive effect on the environment. The
environmental variables included environmental awareness and the number of
environmental programs households are engaged in. Environmental awareness was
measured in the form of importance of environmental quality to the individual, i.e.
important (e.imp), neutral (e.ntrl) and unimportant (e.unimp). Only 2% considered the
environmental quality as unimportant to them, 15% responded to be neutral, and 84%
claimed the environmental quality as an important factor. The importance of the
environment was assumed to affect only the first step in the decision process, i.e. whether
or not they are WTP for a collection program.
The variable #envp was defined as the number of environmentally friendly
programs a household participates in which ranged from 0-5. The programs considered
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included recycling, composting, water conservation, energy conservation, and use of
environmentally friendly products. Only 2% responded they are currently not involved in
any of these practices. Nineteen percent of the sampled population participates in one of
these activities, 19% of the households are engaged in two of these programs, 24% in three
programs, 27% in four programs, and 9% in all five activities. The most practiced activity
is recycling, followed by energy conservation practices and water conservation practices.
The expectation was that the number of environmental programs household are engaged
in, will not only determine willingness to pay (step 1), but it would also affect how much
households are willing to pay (step 2).
Unwanted Pharmaceuticals (Phar)
The presence of unwanted pharmaceutical in the household over the last 12 months
(unmed) may influence their WTP. About 25% of the individuals did not have unused or
unwanted pharmaceuticals, and 75% did have. Respondents were also asked about the
number of prescriptions (#Rx) they would be likely to drop off at a collection point in the
future. The response was included as a reference to the potential amount of prescriptions
within the household, which on average was 2.03. These two variables were included in
the model to help explain the participation behavior based on the existence of unwanted
pharmaceuticals in a household. It is presumed that these variables would have a positive
effect on the WTP per prescription and WTP per visit. Intuition suggests that the presence
of unwanted medications in a household will determine if they would be willing to pay,
but not how much, while the number of prescriptions the household is likely to dispose of
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may have a negative effect on the level of participation, i.e. how much they are willing to
pay.
A dummy variable was also added to capture respondents that have participated in
a medicine collection program before (part). About 350 people have previously
participated either in a permanent collection, single day collection program, or mailed back
their medicines. The expectation is that this variable will have a positive impact on WTP
for such programs.
Socio-economic Variables (Dem)
The demographic factors included average household income, number of people in
the household, college education, age and gender. The five categories for average annual
household income were defined as: $0.00-$30,000 (inc0), $30,001-$45,000 (inc30),
$45,001-$60,000 (inc45), $60,001-$75,000 (inc60), and over $75,000 (inc75). In Table
4.4, the percentage of individuals from each income level for each expressed willingness
to pay is shown. Interestingly, 53% of the individuals that expressed WTPP zero, had an
annual household income corresponding to either tail of the distribution (inc0 or inc75+).
In line with the literature, we observe a trend of the percentage of people from lower
income groups decreasing for each bid amount, but the number of individuals from higher
income level increases with bid amounts. The same behavior was observed when
comparing income with willingness to pay per visit. It is expected that households with a
higher income will have a higher willingness to pay both per prescription and per visit
because they have more disposable income, assuming all other variables are constant.
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Table 4.4: Proportion of Individual’s WTPP Given Annual Household Income

Annual Household
Income [MUSD]

Willingness to Pay per Prescription [USD]
Variable [%]

$0.00

$0.01$1.00

$1.01$2.00

$2.01$3.00

$3.00+

Total

$0-$30

29.36

24.80

16.67

10.47

18.87

25.68

$30.01-$45

18.59

19.29

15.74

11.63

5.66

17.49

$45.01-$60

17.05

17.32

18.52

15.12

5.66

16.63

$60.01-$75

11.28

12.60

16.67

31.40

11.32

13.35

$75.01+

23.72

25.98

32.41

31.40

58.49

26.85

The average size of the households is 2-3 persons. The number of people in a
household (#pple) presumes that with more members in a family, the number of unwanted
pharmaceuticals in a house might be higher. Therefore, the risk of accidental or intentional
abuse of the medicines can increase. For this reasons, it is expected that the number of
people in a household will have a positive effect on WTP.
Education, age and gender do not define households as a whole but they do provide
some information regarding the potential use of pharmaceutical take-back programs. To
control for the level of education, a dummy variable to describe those individuals with a
college degree or higher (edu) was included. Sixty-seven percent of our sample population
has at least a college degree, while for 33%, their highest level of completed education is
high-school. Education may have a positive impact on environmental awareness, and can
then affect the decision of an individual regarding properly disposal of their medications.
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The age groups considered for our analysis were 18-45 years old (age18), 46-65
years old (age46), and over 65 years old (age65). The literature suggests a negative
correlation between age and environmentally friendly practices (Kotchen, et al., 2009,
Torgler, et al., 2008). The same relationship is observed in the data, as shown in Table 4.5.
The percentage of individuals from the first age group (age18) increases as consumers are
willing to pay a higher amount. In other words, the proportion of young adults in relation
to other age groups increases as the bid amount goes up. The inverse relationship is
observed for older citizens. The presumption is that as people grow old, the number of
prescriptions in their homes increase, therefore age has a negative effect on how much a
person would be willing to pay to drop off their medications. This is logical because
economic theory indicates quantity has an inverse relationship with price.
Table 4.5: Proportion of Individual’s WTPP Given Age Group

Age [years old]

Willingness to Pay per Prescription [USD]
Variable [%]

$0.00

$0.01$1.00

$1.01$2.00

$2.01$3.00

$3.00+

Total

18-45

45.38

47.24

71.30

87.21

84.91

52.38

46-65

37.82

34.32

21.30

9.30

11.32

32.71

65+

16.79

18.50

7.41

3.49

3.77

14.91

For gender (male), the expectancy following other studies is that women have a
stronger preference to participate in environmental programs than men, and as such would
be willing to pay more (Ferreira and Moro, 2013, Kotchen, et al., 2009).
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4.2.2

Methodology: Censored Regression Models

A significant number of respondents, accounting for 60% of the sample population,
reported zero WTP (both per prescription and per visit). Tobin (1958) was the first to
propose a censored regression model, the Tobit model, to analyze such data with significant
zero observations. The model has been used to analyze consumption patterns and behavior
from household or individual surveys where a significant number of respondents report
zero consumption. The Tobit model is defined as:
𝑦𝑖∗ = 𝒙′𝒊 𝜷 + 𝜀𝑖 , 𝜀𝑖 ~𝑁(0, 𝜎 2 ),

(5.1)

with a censoring rule such that:
𝑦𝑖 = 0 if 𝑦𝑖∗ ≤ 0
𝑦𝑖 = 𝑦𝑖∗ if 𝑦𝑖∗ > 0

(5.2)

where 𝑦𝑖∗ represents the desired contribution of subject i, 𝛽 is a vector of exogenous
variables, and 𝑦𝑖 is the observed contribution.
The likelihood function is given by:
𝑥𝑖 𝛽

𝑓(𝑦|𝑥𝑖 ) = {1 − 𝛷 (

𝜎

1(𝑦=0)

)}

−1
2

[(2𝜋) 𝜎

−1

−(𝑦−𝑥𝑖 𝛽)2

𝑒𝑥𝑝 {

2𝜎2

1(𝑦>0)

}]

(5. 3)

where Φ is the standard normal cumulative distribution function and 1(y=0) and 1(y>0) are
the exponential indicator functions.
For the purpose of the analysis, the empirical Tobit model was defined as:
𝑦𝑖∗ = 𝑬𝒏𝒗𝒊 𝜷𝑬𝒏𝒗 + 𝑷𝒉𝒂𝒓𝒊 𝜷𝑷𝒉𝒂𝒓 + 𝑫𝒆𝒎𝒊 𝜷𝑫𝒆𝒎 +𝜀𝑖 , 𝑖 = 1, … , 𝑛.

(5.4)

where 𝑬𝒏𝒗𝒊 is the vector set of independent environmental variables including e.imp, e.ntrl
and #envp; 𝑷𝒉𝒂𝒓 is the vector set of pharmaceutical related variables including unmed,
part and #Rx; 𝑫𝒆𝒎 is the vector set of socioeconomic variables including #pple, inc30,
inc45, inc60, inc75, edu, age18, age46, and male. Two different models with different
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dependent variables (𝑦𝑖∗ ) were estimated, WTPP and WTPV. In the Tobit model, given its
parametrization, the factors that determine the probability of consumption are the same
factors that affect the level of consumption.
Cragg (1971) proposed a more general and flexible model where the decision of
participation and the level of consumption (amount willing to pay) are determined by two
different stochastic processes. This model considers the possibility that factors influencing
willingness to pay and factors influencing the amount paid may be different. The maximum
likelihood estimator in the first hurdle can be obtained using a Probit estimator, and the
second hurdle can be estimated from a truncated normal regression model. The log
likelihood function is given by:
−1

𝑓(𝑤, 𝑦|𝒙𝟏 , 𝒙𝟐 ) = {1 − 𝜙(𝒙𝒊 𝛾)}1(𝑤=0) [𝜙(𝒙𝟏 𝛾)(2𝜋) 2 𝜎 −1 𝑒𝑥𝑝 {

−(𝑦−𝒙𝟐 𝛽)2
2𝜎 2

1(𝑤−1)
𝛽
}⁄𝜙 (𝒙𝟐 ⁄𝜎)]

(5.5)

where w is a binary indicator equal to 1 if y>0 and 0 otherwise, and 𝜸 and 𝜷 are different
vectors that determine participation and consumption. This model was estimated using
Stata 13.1 with Burke’s (2009) estimation command craggit.
In the Double Hurdle (DH) Model, the estimation vector for each stage consisted
of different variables. Just as with the Tobit model, the DH model was estimated twice with
WTPP and WTPV as the dependent variables. The first stage for the probit estimation was
defined as:
∗
𝑦𝑖,1𝑠𝑡
= 𝑬𝒏𝒗𝒊 𝜷𝑬𝒏𝒗 + 𝑷𝒉𝒂𝒓𝒊 𝜷𝑷𝒉𝒂𝒓 + 𝑫𝒆𝒎𝒊 𝜷𝑫𝒆𝒎 +𝜀𝑖 , 𝑖 = 1, … , 𝑛.

(5.6)

where 𝑬𝒏𝒗𝒊 is the vector set of independent environmental variables including e.imp, e.ntrl
and #envp; 𝑷𝒉𝒂𝒓𝒊 is the vector set of pharmaceutical related variables including unmed,

87
part and #Rx; 𝑫𝒆𝒎𝒊 is the vector set of socioeconomic variables including #pple, inc30,
inc45, inc60, inc75, edu,age18,age46, and male.
For the second stage, the variables related to the level (how much) of willingness
to pay were:
∗
𝑦𝑖,2𝑛𝑑
= 𝑬𝒏𝒗(𝒓𝒆𝒔)𝒊 𝜷𝑬𝒏𝒗 + 𝑷𝒉𝒂𝒓(𝒓𝒆𝒔)𝒊 𝜷𝑷𝒉𝒂𝒓 + 𝑫𝒆𝒎𝒊 𝜷𝑫𝒆𝒎 +𝜀𝑖 , 𝑖 = 1, … , 𝑛.

(5.7)

where the only environmental variable included in 𝑬𝒏𝒗(𝒓𝒆𝒔)𝒊 is #envp, 𝑷𝒉𝒂𝒓(𝒓𝒆𝒔)𝒊 includes
part and #Rx and 𝑫𝒆𝒎𝒊 which includes the same variables as the first stage. Initially, the
respective states were included as variables (Geoi) in the model. However, further analysis
suggested an over specification given a non-statistical T-student nor joint significance. To
test this hypothesis, an F-test was used, with H0: 𝜷𝑮𝒆𝒐 = 0 and Ha: 𝜷𝑮𝒆𝒐 ≠ 0. The results
were χ2 of 12.36 with Prob>chi2 of 0.26 for the WTP per prescription; and χ2 of 13.73 with
Prob>chi2 of 0.18 for WTP per visit models. We therefore fail to reject the null hypothesis
that the model supports the imposed restriction of 𝜷𝑮𝒆𝒐 = 0.
The estimations obtained by both models facilitate the calculation of the probability
that y=0, 𝑃(𝑦𝑖 = 0|𝑥1𝑖 ) and the probability that y>0, 𝑃(𝑦𝑖 > 0|𝑥1𝑖 ). From Cragg’s model,
the probabilities are calculated as:
𝑃(𝑦𝑖 = 0|𝑥1𝑖 ) = 1 − 𝛷(𝑥1𝑖 𝛾)

(5.8)

𝑃(𝑦𝑖 > 0|𝑥1𝑖 ) = 𝛷(𝑥1𝑖 𝛾)

(5.9)

Given these probabilities, the expected value of y can be estimated, given x and that yi>0,
𝐸(𝑦𝑖 |𝑦𝑖 > 0, 𝑥2𝑖 ) and the unconditional expected value, 𝐸(𝑦𝑖 |𝑥2𝑖 ) the following way:
𝐸(𝑦𝑖 |𝑦𝑖 > 0, 𝑥2𝑖 ) = 𝑥2𝑖 𝛽 + 𝜎 × 𝜆(𝑥2𝑖 𝛽 ⁄𝜎)

(5.10)

𝐸(𝑦𝑖 |𝑥1𝑖 , 𝑥2𝑖 ) = 𝛷(𝑥1𝑖 𝛾){𝑥2𝑖 𝛽 + 𝜎 × 𝜆(𝑥2𝑖 𝛽 ⁄𝜎)}

(5.11)
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with 𝜆(𝑐) as the inverse Mills ratio 𝜆(𝑐) = 𝜙(𝑐)/𝛷(𝑐) where 𝜙(𝑐) is the standard normal
probability distribution function. From the estimated mean willingness to pay per
prescription and per visit, the total annual benefits of an unwanted pharmaceuticals
program were estimated.

4.3
4.3.1

Results and Discussion

Unwanted Medicine Behavior and Disposal Practices

In addition to the willingness to pay per prescription and per visit, the survey
responses provided information about the reasons for pharmaceuticals accumulation and
disposal practices. An estimated 61% of the households that participated in the survey have
had unwanted pharmaceuticals in their home over the past 12 month. The main reasons for
the accumulation of these substances are: users stopped taking the medication before the
supply ran out (33%), not knowing what to do with the expired medicines (32%), and a
change in medication (25%).
Regarding disposal practices, about 68% of respondents reported they had disposed
of unwanted pharmaceuticals at some point in the past. In line with other studies (Kotchen,
et al., 2009, Kuspis and Krenzelok, 1996), the most common disposal method reported is
throwing the substances in the trash (44%), followed by flushing them down the toiler or
sink (29 %). Most people dispose the pharmaceuticals of their own households, while a
few report doing so for other relatives or their pets.
A total of 378 persons reported they have participated in some kind of take-back
program in the past. These programs include single day collection programs, mail back
programs, and permanent collection boxes at pharmacies, police departments, hospitals and
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other health care centers. Three out of 4 users have participated only in one type of
program, while 25% have used at least two different types of collection centers. The most
popular types of programs are the single-day collection events, followed by the permanent
collection boxes at police departments and pharmacies. Mail programs are the least
popular, accounting only for 7% of the participation rates. On average, users have been
participating for 19 months in these programs, and they travel an average of 12.5 miles to
dispose 5-6 different types of prescriptions.

4.3.2

Double Hurdle Model

The estimation of the participant’s willingness to pay per prescription for the Tobit
and Double Hurdle model are summarized in Table 4.6 and WTP per visit in Table 4.7.
𝛽
The Tobit model is nested within Cragg’s alternative because when 𝒙𝟏 = 𝒙𝟐 and 𝛾 = ⁄𝜎,
the models are identical. To assess which is the most appropriate specification, there is a
need to determine if the individual’s decision on the extent of participation (WTP) is the
result of a step-wise decision or not. The first decision would consist of determining
whether the individual would be willing to pay, and the second is the amount they would
be willing to pay, given that the individual is willing to pay. If this is the case, a Double
Hurdle model would be the most appropriate approach. Otherwise, if no evidence indicates
a step-wise decision, a more general Tobit model would suffice. A log-likelihood test was
used to determine which model is the most appropriate for the data. The results are a χ2 of
53.72 for WTP per prescription and χ2 of 41.81 for the WTP per visit, therefore the null
hypothesis that the decision process is only a one step process is rejected. That means the
DH is the most appropriate specification for the study.
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The importance of determining the correct model can be appreciated when
comparing the independent variables that determine participation in each case. From Table
4.6, the Tobit model results show that environmental importance (e.imp) and at least a
college education (edu) affect WTP and the amount WTP at a significance level of 10 %.
Previous participation in a take back medicine program (part) and gender (male) are
significant at a 5 % level; while number of prescriptions likely to dispose of (#Rx), average
annual household income above $60,000 dollars (inc60 and inc75), and age 18-45 years
old (age18) are significant at a 1% level. Similar results are found for the Tobit model
determining WTPV in Table 4.7. The difference between these estimations is the statistical
significance level of having had unwanted medications in the household over the past 12
months (unmed) and the lack of significance of the gender (male.)
The results from the Double Hurdle model are also presented in Tables 4.6 and 4.7
respectively for WTP per prescription and for willingness to pay per visit. From Table 4.6,
the decision of WTPP is determined by the number of prescriptions likely to dispose of
(#Rx), the presence of unwanted pharmaceuticals in the household (unmed), annual
household income between $60,000 -$75,000 (inc60), annual household income above
$75,000 (inc75), age (yrs18), and the number of people living in a household (#pple).
The factors that determine the level of consumption are the number of
environmental programs households are involved in (#envp), the number of prescriptions
that consumers would get rid of (#Rx), age (age18), gender (male), and income level (inc60
and inc75). Thus, we can conclude that the factors that influence a person’s decision to
participate in a paid pharmaceutical collection program are different from the factors that
determine how much they are willing to pay per prescription. A similar observation applies
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when individuals are asked for their willingness to pay per visit, as observed in Table 4.7.
The only difference is the independent variables that influence the decision process.
Environmental Practices (Env)
The amount consumers are willing to pay per prescriptions (Table 4.6) is influenced
by the number of environmental programs the household is engaged in (#envp). Proenvironmental behavior is associated with higher environmental awareness, thus the
expectation was a positive effect on how much individuals are willing to pay for a drug
collection program. However, the results suggest participation in other environmental
program has a negative effect on the consumption level of individuals. The possible
explanation to this finding is that, if participation in other environmental programs involves
additional costs (e.g. higher price, participation fees, and transportation time), then the
more programs a family is enrolled in, the amount of disposable income left that the
household is willing to spend on other environment programs is lower. Furthermore,
individuals may consider the program to have a positive benefit, but the marginal benefits
perceived from this specific program in contrast with another environmental programs may
be lower. Thus, there may be some trade-off or substitution effect. From Table 4.7, the
number of pro-environmental programs is not statistically significant when determining
the WTP and the amount WTP per visit.

92
Table 4.6: WTP per Prescription from Tobit and DHM Estimations.
Variable
e.ntrl
Env

e.imp
#envp
part

Phar

unmed
#Rx
#pple
inc30
inc45
inc60

Dem

inc75
edu
age18
age46
male
_cons
sigma_cons
N

* p<0.1; ** p<0.05; *** p<0.01

Tobit

Double Hurdle

Coefficients
-0.168

Participation
-0.084

Consumption

(0.480)

(0.310)

0.884*

0.465

(0.460)

(0.298)

-0.069

0.012

-0.211***

(0.050)

(0.034)

(0.077)

0.296**

0.127

0.312

(0.127)

(0.086)

(0.192)

0.174

0.185**

(0.140)

(0.091)

0.150***

0.102***

0.060*

(0.026)

(0.019)

(0.032)

-0.050

-0.052*

0.051

(0.045)

(0.030)

(0.069)

0.169

0.116

0.103

(0.179)

(0.116)

(0.324)

0.203

0.122

0.229

(0.183)

(0.120)

(0.315)

0.633***

0.343***

0.727**

(0.192)

(0.129)

(0.302)

0.531***

0.266**

0.670**

(0.169)

(0.111)

(0.283)

0.234*

0.138

0.007

(0.128)

(0.084)

(0.225)

0.940***

0.408***

1.662***

(0.186)

(0.121)

(0.393)

-0.029

-0.071

0.457

(0.187)

(0.120)

(0.397)

0.291**

0.075

0.589***

(0.122)

(0.082)

(0.183)

-2.412***

-1.438***

-0.971*

(0.510)

(0.327)

(0.567)

1.666***

1.315***

(0.059)

(0.086)

1,284

1,284
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Table 4.7: WTP per Visit from Tobit and DHM Estimations.
Variable
e.ntrl
Env

e.imp
#envp
part

Phar

unmed
#Rx
#pple
inc30
inc45
inc60

Dem

inc75
edu
age18
age46
male
_cons
sigma_cons
N

* p<0.1; ** p<0.05; *** p<0.01

Tobit

Double Hurdle

Coefficient
-0.626

Participation
-0.298

Consumption

(0.850)

(0.300)

1.429*

0.354

(0.810)

(0.287)

-0.070

0.013

-0.200

(0.090)

(0.034)

(0.132)

0.558**

0.143*

0.485

(0.228)

(0.086)

(0.333)

0.646**

0.242***

(0.255)

(0.091)

0.316***

0.111***

0.190***

(0.046)

(0.020)

(0.053)

-0.107

-0.068**

0.177

(0.081)

(0.030)

(0.126)

0.255

0.130

-0.268

(0.324)

(0.116)

(0.600)

0.523

0.174

0.610

(0.328)

(0.120)

(0.555)

1.157***

0.353***

1.371**

(0.346)

(0.129)

(0.545)

1.121***

0.261**

1.765***

(0.306)

(0.112)

(0.514)

0.451*

0.151*

0.107

(0.232)

(0.084)

(0.399)

1.552***

0.434***

2.032***

(0.335)

(0.122)

(0.626)

-0.095

-0.040

0.186

(0.335)

(0.120)

(0.647)

0.233

0.053

0.227

(0.219)

(0.082)

(0.321)

-4.432***

-1.338***

-1.721*

(0.901)

(0.317)

(0.964)

3.013***

2.382***

(0.105)

(0.149)

1,284

1,284
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Unwanted Pharmaceuticals (Phar)
An individual’s decision of willingness to pay for each prescription (Table 4.6) and
per visit to a pharmaceuticals disposal program (Table 4.7) is influenced positively by the
number of prescriptions (#Rx). It may be that the number of medicines a person is likely to
dispose-off is a reflection of the number of medicines accumulated in their household.
Thus, the utility from using the program is higher as the number of prescriptions increases,
and the risks related with improper storage such as accidental poisoning and abuse
decrease. The same reasoning applies for the effect of whether the household has had
unwanted medicines at the home the past 12 months (unmed), when determining
participation. Perhaps, it may also explain the findings in Table 4.7., i.e., the number of
prescriptions (#Rx) also has a statistically significant positive effect in the level of
consumption for both models.
Socio-economic Variables (Dem)
The expectation was that household size (#pple) would have a positive effect on the
participation decision in WTP as a result of higher risk of accidental poisoning and drug
abuse. However, the results suggest there is a statistically significant negative effect in both
models (Table 4.6 for WTPP and Table 4.7 for WTPV). The negative association may
result from higher expected expenses in larger households that constraint the proportion of
the budget used for pro-environmental activities.
Annual household income is another factor that influences the individual’s
participation decision positively. The effect is statistically significant at the 1% level for
inc60 and at the 5% for inc75 (Table 4.6). We also expected the income to be a statistically
significant factor when determining the amount consumer would potentially pay (Table
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4.7). The model estimations suggest the expectations hold with statistical confidence (5%).
The estimated coefficients support findings in the literature of a positive relationship
between household income and willingness to pay for an environmental program.
People age 18-45 have a statistical positive correlation (1% confidence level) with
the participation and consumption decision process for both models. As alluded earlier, on
average, younger adults are more willing to pay for a pharmaceutical collection program.
Furthermore, although not statistically significant, we observe a negative correlation
between willingness to pay for an environmental program and the older age group.
Studies on environmental program participation have found women are more likely
to participate than men. The results from Table 4.7 for WTPV suggest the amount
individuals are willing to pay per visit (2nd stage) is influenced, at a statistically
significantly level (1 %) by male gender. The difference with previous studies might be
explained by the fact that, although women tend to express more environmental concern
than men, this does not necessarily imply they are more likely to actually engage in
environmental actions compared to men (Blocker and Eckberg, 1997).
To assess the fit of the estimated model, the predicted probabilities of individuals
at each hurdle of the model (participation and consumption) were estimated and compared
with the data set. The results are summarized in Table 4.8 and Table 4.9. Sixty-four percent
of survey respondents were not willing to pay for a medicine collection program, both per
prescription and per visit. The model predicts that there is 39% probability of participants
willing to pay per prescription and 40% probability of willingness to pay per visit. The
model’s predicted probability of individual’s participation is lower than the observed
participation rates of the complete sample population by 3% for WTPP and 4% for WTPV.
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Table 4.8: Percentage of Respondents WTPP from Sample vs.
Predicted Probabilities Calculated from DHM.
Model

Variable

Observed
WTP per
Prescription
Predicted
Probability
WTP per
prescription

Observations

Mean

St. Dev

Unwilling
(WTP=0)

2016

0.64

Willing
(WTP>0)

2016

0.36

0.47

Unwilling
(WTP=0)

1287

0.61

0.16

Unwilling
(WTP=0)

1287

0.39

0.16

Table 4.9: Percentage of Respondents WTPV from Sample vs.
Predicted Probabilities Calculated from DHM.
Model
Observed
WTP per
Visit
Predicted
Probability
WTP per
Visit

Variable

Observations

Mean

St. Dev

Unwilling
(WTP=0)

2018

0.64

Willing
(WTP>0)

2018

0.36

0.48

Unwilling
(WTP=0)

1287

0.60

0.17

Unwilling
(WTP=0)

1287

0.40

0.17
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Based on the DH model results presented in Table 4.6 and Table 4.7, the mean
willingness to pay per prescription and per visit were estimated and are presented in Table
4.10. The estimated unconditional mean willingness to pay per prescription is $0.53 and
the mean willingness to pay for those who have a positive willingness to pay per
prescription is $1.25 (Table 4.10). In the case of WTP per visit, the mean value for all
consumers is $1.03, and $2.33 for those that move on to the second hurdle.
Table 4.10: Estimated Mean WTP from DHM.
Dependent
Variable
WTP per
Prescription

WTP per Visit

Conditional WTP

Observations

Mean

St. Dev

WTP E(y|y>0)

1293

$1.25

0.43

WTP E(y)

1287

$0.53

0.40

WTP E(y|y>0)

1293

$2.33

0.80

WTP E(y)

1287

$1.03

0.78

Table 4.11: Estimated Mean WTP from DHM from Previous Program Participants
(part=1).
Dependent
Variable
WTP per
Prescription

WTP per Visit

Conditional WTP

Mean

St. Dev

WTP E(y|y>0)

$1.40

0.55

WTP E(y)

$0.72

0.53

WTP E(y|y>0)

$2.64

1.01

WTP E(y)

$1.42

1.03
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The mean willingness to pay for only respondents that had previously participated
in a medicine take-back were also estimated (Table 4.11). The results suggest that these
individuals are willing to pay a slightly higher price per prescription and per visit. For
example, the unconditional mean WTP for all respondents per prescription is $0.53 (Table
4.10), while those that have participated in previous program are willing to pay $0.72 per
prescription (Table 4.11), $0.17 more. Similarly, the unconditional WTP per visit for all
individuals is $1.03 and $1.42 for those that have previously participated in a program; a
difference of $0.39. The difference in the mean WTP given a predicted positive
participation in the first stage of the model between all individuals and recurrent
participants is $0.15 per prescription and $0.31 per visit.

4.3.3

Total Annual Benefits: Homogeneous Population

With the estimated mean willingness to pay for each model, the total annual
benefits for a pharmaceutical program were calculated for different assumptions: a) total
population in the region; b) number of households in the region; c) previous participation
in a take-back program; d) widespread participation. We used the U.S. Census Bureau
population and household data from 2013 in the Great Lakes region to estimate mean
willingness to pay per prescription and per visit, and the average number of prescriptions
likely to dispose reported by respondents. The total population (millions of people) of at
least 18 years old per state is as follows: Indiana 5.0; Illinois 9.9; Ohio 8.9; Michigan 7.7;
Wisconsin 4.4; Minnesota 4.1. The number of households (millions of households) per
state is: Indiana 2.5; Illinois 4.8; Ohio 4.6; Michigan 3.8; Wisconsin 2.3; Minnesota 2.1
(U.S. Bureau, 2014). For the calculation of the annual benefits given the WTP per
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prescription for the entire sample, the average number of prescriptions used was 2.03 and
for those who had previously participated in a program, i.e. part=1, 4.65 prescriptions.
With these assumptions, we consider the total annual benefits estimated to be a
conservative approach, given that the assumptions imply a single participation in the year.
Scenario 1 (per prescription):
First, we estimated the total annual benefits per state given the unconditional mean
WTPP ($0.53) based on estimates from the entire sample (Table 4.10) and the total
population. The total annual benefits per state are summarized in column (a) of Table 4.12.
For the Great Lakes region, the estimated social benefits from pharmaceutical programs
are $43 million for the total population. Participants of a medicine collection program
usually dispose of the medications from the household. Thus, a more conservative
estimation is to consider the total number of households per state. The annual benefits from
this estimation total $21.6 million per year, as shown in column (b) Table 4.12.
The econometric model indicated that the estimated unconditional mean WTPP for
recurrent participants of pharmaceutical programs is higher than the unconditional average
from the entire sample population ($0.53 vs $0.72). The number of prescriptions likely to
dispose also varied (2.03 vs 4.65). Thus, we also estimated the annual benefits of a
collection program for recurrent participants. We assumed a participation rate of 18%.
Under these assumptions, the yearly benefits of drug collection program in the Great Lakes
add to $12.5 million (column (c) of Table 4.12). Lastly, a hypothetical scenario assuming
awareness campaigns resulted in widespread participation of households was estimated.
We assumed the mean WTPP for part=1 and 4.65 disposed prescriptions. The value of the
program under this scenario is $67.2 million per year (column (d) in Table 4.12).
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Table 4.12: Annual Benefits Calculated from WTPP per Scenario. ($Million)
(a)

(b)

(c)

(d)

No.
Households

Current
Participation

Widespread
participation

Indiana

Total
Population
$5.4

$2.7

$1.6

$8.3

Illinois

$10.6

$5.1

$3.0

$16.0

Ohio

$9.6

$4.9

$2.8

$15.3

Michigan

$8.2

$4.1

$2.4

$12.8

Wisconsin

$4.8

$2.5

$1.4

$7.7

Minnesota

$4.5

$2.3

$1.3

$7.1

Total

$43.0

$21.6

$12.5

$67.2

State

Scenario 2 (per visit):
The annual benefits that result from the estimated mean willingness to pay per visit
were also estimated. The assumptions made included a single visit per year for the general
population, and 2 annual visits for recurring participants. The total annual benefits are
summarized in Table 4.13. For a single visit by the entire population, column (a), the total
annual benefit is $41.2 million; and considering participation at a household level, the
benefit amounts to $20.7 million, column (b). For two visits for recurring participants, the
societal value of the program is estimated to be $10.6 million for current participation rates,
column (c), and $57.0 assuming widespread participation, column (d). These estimates are
very similar to those estimated by the WTP per prescription.
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Table 4.13: Annual Benefits Calculated from WTPV and per Scenario ($Million).
(a)
State

(b)

(c)

(d)

Total
Population

No.
Households

Current
Participation

Widespread
Participation

Indiana

$5.1

$2.6

$1.3

$7.1

Illinois

$10.2

$4.9

$2.5

$13.6

Ohio

$9.2

$4.7

$2.4

$13.0

Michigan

$7.9

$3.9

$2.0

$10.9

Wisconsin

$4.6

$2.4

$1.2

$6.5

Minnesota

$4.3

$2.2

$1.1

$6.0

Total

$41.2

$20.7

$10.61

$57.02

Scenario 3 (per prescription for WTP E(y|y>0):
Next, we estimated the total annual societal value for the proportion of the sample
that proceeded to the second hurdle of the model, WTP E(y|y>0). Under these assumption,
the benefits of only those willing to pay to participate in a medicine disposal program are
considered. Recalling from Table 4.10 and Table 4.11, the average WTPP for this sample
of the population is $1.25 and $1.40 for previous participants. Under this assumption, the
number of prescriptions and participation rates do not vary. From the model, 39% of the
population is expected to have a mean willingness to pay per prescription greater than 0.
The estimated total benefits for various assumptions are reported in Table 4.14. The total
benefit for the total population is estimated to be $39.6 million while the benefit for the
current program participants is $9.5 million. The difference between the benefits estimated
using the conditional mean WTP and the unconditional mean WTP are -7.9%, when
considering the whole population, and -24.1% when estimating for recurring participants.
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Scenario 4 (per visit for WTP E(y|y>0):
The annual benefits estimated with the conditional mean per visit from the second
hurdle of the model were also calculated (Table 4.15). In this case, the predicted probability
from Table 4.9 of individuals with WTPV>0 is 40%. The mean values for the entire data
set is $2.33 and $2.64 for part=1. The total monetary value is estimated at $37.3 for the
total population, column (a), $18.7 for the number of households, column (b), $7.9 for
current participants, column (c), and $42.4 for widespread participation, column (d).
Details by state are summarized in Table 4.15. Similarly to the per prescription case, the
estimated benefits are lower under these assumptions (-9.5% for all, and 25.5% for part=1).

Table 4.14: Annual Benefits Calculated from WTPP and WTP>0 per Scenario($Million).
(a)
State

(b)

(c)

(d)

Total
Population

No.
Households

Current
Participation

Widespread
Participation

Indiana

$4.9

$2.5

$1.2

$6.3

Illinois

$9.8

$4.7

$2.3

$12.1

Ohio

$8.8

$4.5

$2.2

$11.6

Michigan

$7.6

$3.8

$1.8

$9.7

Wisconsin

$4.4

$2.3

$1.1

$5.8

Minnesota

$4.1

$2.1

$1.0

$5.4

Total

$39.6

$19.9

$9.5

$51.0
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Table 4.15: Annual Benefits Calculated from WTPV and WTP>0 per Scenario ($Million).

(a)
State

(b)

(c)

(d)

Total
Population

No.
Households

Current
Participation

Widespread
Participation

Indiana

$4.7

$2.3

$1.0

$5.3

Illinois

$9.2

$4.5

$1.9

$10.1

Ohio

$8.3

$4.3

$1.8

$9.7

Michigan

$7.2

$3.6

$1.5

$8.1

Wisconsin

$4.1

$2.1

$0.9

$4.8

Minnesota

$3.8

$2.0

$0.8

$4.5

Total

$37.3

$18.7

$7.9

$42.4

Average Annual Benefits:
In summary, the results obtained suggest that pharmaceutical collection programs
provide a positive value to society in the Great Lakes area. To estimate the value of
medicine take-back programs under each assumption (total population, total households,
participant households and widespread participation), an average of the total annual
benefits estimated from Scenario 1 and 3 for WTPP, and Scenario 2 and 4 for WTPV was
calculated. Assuming widespread participation, we calculated the potential average value
of pharmaceutical collection programs in the Great Lakes region. This approximation
considers a full engagement from the entire society. The total estimated value is $59.1
million per year for WTPP from Scenarios 1 and 3, and $49.71 million per year with WTPV
from Scenarios 2 and 4. Although this assumption is very unlikely, the estimation provides
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a potential ceiling, assuming all other factors remain constant, of the monetary value of the
program. This information can help program providers and policymakers make decisions
in the future.
The benefit to current participants of pharmaceutical disposal programs (c) in the
Great Lakes region is estimated to be $11.00 million per year from WTPP and $9.26
million per year from WTPV. However, these estimations disregard any value other
members of society may associate with the program. For this reason, we consider $9.26
million per year as the floor value of these programs in the region. As awareness and
participation increases, the estimated value will also increase.
From the first two assumptions, total population 18 and older and total number of
households, the estimated total annual benefits in the Great Lakes are between $20.75 and
$41.30 million under the WTPP estimations, and $19.70 - $39.25 million from the WTPV
model. Since the sample used to estimate the mean value of the program does not provide
information on how many persons per household would participate in a program, it is not
possible to determine which population variable to use. However, the estimated range is a
good approximation of where the total value of the program would lie and provides
information for a sensitivity analysis in a cost-benefit evaluation.

4.3.4

Total Annual Benefits: Heterogeneous Population

Given that heterogeneity persists among individuals and potentially the states, an
alternative circumstance where the WTP per prescription and per visit varied across states
was considered. To obtain the mean willingness to pay per states, the state dummies were
incorporated into the regression. The estimated values per state are reported in Table 4.16
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and Table 4.17. Illinois residents are willing to pay the highest amount, unconditional mean
WTP of $0.70 and mean WTP of $1.44 (Table 4.16). Illinois has one of the highest median
income in the Mid-west. (U.S. Bureau, 2014). Higher income has been positively correlated
with a positive willingness to pay. In addition, concerns for pharmaceuticals in the drinking
water source and the Michigan Lake since the 2000’s have led to awareness campaigns and
promotion of disposal programs in collaboration with the public and private sector in
Illinois. Illinois is a fairly liberal state, and a study in California found that individuals with
democratic party affiliation were 13% more willing to pay for a surcharge for the creation
of a medicine take-back program (Kotchen, et al., 2009). All these factors could play a role
in the higher WTP when compared to the other states.
Indiana is the state with the 2nd highest mean WTPP and WTPV. The geographical
proximity with Illinois, support from IISG to both Indiana and Illinois, and the high number
of deaths from prescription drugs are possible explanations for this finding.
Table 4.16: Mean WTP per Prescription per State from DHM
State

WTPP
E(y)

St Dev
E(y)

WTPP
E(y|y>0)

St Dev
E(y|y>0)

Indiana

$0.50

0.38

$1.21

0.40

Illinois

$0.70

0.47

$1.44

0.49

Ohio

$0.41

0.32

$1.07

0.36

Michigan

$0.48

0.35

$1.11

0.36

Wisconsin

$0.42

0.26

$1.21

0.38

Minnesota

$0.46

0.28

$1.19

0.36
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Table 4.17: Mean WTP per Visit per State from DHM
State

WTPV
E(y)

St Dev
E(y)

WTPV
E(y|y>0)

St Dev
E(y|y>0)

Indiana

$1.04

0.85

$2.39

0.85

Illinois

$1.36

0.88

$2.63

0.84

Ohio

$0.78

0.64

$2.02

0.66

Michigan

$0.93

0.73

$2.12

0.69

Wisconsin

$0.81

0.52

$2.15

0.65

Minnesota

$0.79

0.48

$2.02

0.57

To estimate the total annual benefits per state, only the total population in the region
(assumptions (a)) and the number of households in the region (assumption (b)) were
considered. The estimations were performed with the unconditional mean willingness to
pay (WTP E(y)), and the conditional willingness to pay (WTP E(y|y>0). In these scenarios,
the assumptions of number of prescriptions, number of visits, and the predicted probability
for each decision stage remained the same as the homogenous case.
Scenario 5 (per prescription):
The benefits using the unconditional mean WTP across the population add up to
$41.6 million assuming a WTP from all the population (a), and $20.8 million for assuming
WTP per household (b) (Table 4.18). From the conditional mean WTP, benefits equal
$38.5 million dollars for total population (a), and $19.3 for total number of households (b)
(Table 4.18). The average from total annual benefits calculated by averaging the mean
results is estimated between $20.1 million to $40.5 million for total number of households
and total population, respectively.
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Table 4.18: Annual Benefits per State Calculated from WTPP ($Million).
WTP E(y)
State

WTP E(y|y>0

(a)Total
Population

(b)No.
Households

(a)Total
Population

(b)No.
Households

Indiana

$5.1

$2.5

$4.8

$2.4

Illinois

$14.0

$6.8

$11.3

$5.4

Ohio

$7.4

$3.8

$7.5

$3.9

Michigan

$7.5

$3.7

$6.8

$3.4

Wisconsin

$3.8

$2.0

$4.2

$2.2

Minnesota

$3.9

$2.0

$3.9

$2.0

Total

$41.6

$20.8

$38.5

$19.3

Table 4.19: Annual Benefits per State Calculated from WTPV ($Million).
WTP E(y)
State

WTP E(y|y>0

(a)Total
Population

(b)No.
Households

(a)Total
Population

(b)No.
Households

Indiana

$5.2

$2.6

$4.8

$2.4

Illinois

$13.5

$6.5

$10.4

$5.0

Ohio

$6.9

$3.6

$7.2

$3.7

Michigan

$7.2

$3.6

$6.5

$3.2

Wisconsin

$3.6

$1.9

$3.8

$2.0

Minnesota

$3.2

$1.7

$3.3

$1.7

Total

$39.6

$19.7

$36.0

$18.0
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Scenario 6:
From the WTPV, the value of pharmaceutical program estimated with the mean
willingness to pay are presented in Table 4.19. The results suggest the value of society
ranges from $19.7 million for total number of households to $39.6 million for total
population, using the unconditional mean. With the conditional mean WTP, the benefits
per year are $18.0 million for total number of households, and $36.0 million for total
population. Averaging both of these estimations, the economic value of pharmaceutical
programs is $18.9 million for total number of households and $37.8 for total population.
From Table 4.18 and Table 4.19, the state with the higher estimated annual benefits
is Illinois, and the lowest estimated annual benefits is Minnesota. These estimates are
slightly lower than the model that assumes a homogeneous sample.

4.4

Policy Implications and Conclusions

Medicine take-back programs have been implemented across the U.S. as a measure
to reduce water pollution from pharmaceutical residues in the environment and reduce the
risk of prescription abuse and accidental poisoning. These programs have a positive value
to society associated with the environmental and public health costs avoided. However,
given the data and market limitations, it is not possible to determine the societal value by
quantifying the avoided costs. A contingent valuation method was used to estimate the
mean annual benefits for the existence of these programs in the Great Lakes region,
associating the amount individuals are willing to pay with the benefits obtained from the
program.
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The results suggest that the decision to pay for a medicine take-back program and
the amount participants are willing to pay are influenced by different factors. Participation
is influenced by the presence and number of pharmaceuticals in the household, annual
income above $60,000 and age 18-45 years old. The level of consumption is influenced by
the age and income level and the number of pills consumers are likely to dispose.
The estimated monetary value calculated from the DH model provides insight into
consumer’s preferences by approximating the societal benefits for these programs. On
average, annual benefits in the Great Lakes region range between $19.5 and $39.7 million.
Costs of existing programs in each state vary by the type of program, size and scope. Some
of the incurred costs may include advertising, secure drop boxes, supplies, costs of
consolidation of medicines at central collection site, warehousing of medicines prior to
disposal, transportation to disposal facility, destruction costs and wages. The specific costs
for each program vary given the type of program and the defined scope. The most economic
type of medicine collection schemes are single day events. The associated costs for these
events are transitory, including planning, advertising, staff, and logistics. Some of the
reported total costs for these events include $6,815 plus voluntary hours of staff for a oneday event organized by the Milwaukee Metropolitan Sewerage District, to $90,000 and
1,980 hours of staff time for 59 events organized during a week in 39 locations by the Bay
Area Pollution Prevention Group in California (IISG, 2009).
Permanent collection programs have continuing costs associated with the
administration, transport and disposal of the medications. Reported costs of these types of
programs have been reported to range from $12,000-$15,000 dollars spent annually to
operate the La Crosse County disposal program of household medications (La Crosse
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County, 2016), to $516,800 spent annually in King County, Washington for 1,033
pharmacy drop sites (KingCounty, 2012). Some programs have reported the incurred costs
per pound or container disposed. In San Mateo County, the pharmaceutical collection
program at three different police stations was estimated to cost $1.57 dollars per pound of
collected medicines (Gordon, 2007). The City of Olmsted Falls, Ohio

developed a

medication disposal program in conjunction with a nearby hospital. To dispose of the
medications, they incur in a $60 dollar fee per 28-gallon container (IISG, 2009). In
Washington State, the estimated cost for a statewide program is $5.60 per pound.
Program providers and policymakers can use the estimated total benefits to perform
a cost-benefit analysis when assessing the implementation of new programs. If benefits
exceed the costs, the implementation of these programs should be considered as a policy
measure to reduce APIs in rivers, lakes, groundwater, drinking water and other ecosystems.
Comparing the total costs of implementation of a single collection program (either single
day or permanent collection site) suggest a favorable cost-benefit ratio, even with a
conservative estimation of the total annual benefits. Moreover, the advertising and
awareness campaigns that would likely be implemented with a program, will increase
participation rates, suggesting a higher mean WTP as observed in the study when the mean
WTP between participants and non-participants was compared. Thus, the societal value of
the programs would more likely be higher than initially estimated.
An assessment of the access to take-back medicine programs suggests a limited
availability to a large percentage of the population (PSI, 2012). As the public becomes
more aware about the risk of improperly disposing their medications, it is very likely the
number of programs across the region will continue to grow. For more programs to be
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established, and a continuous support to the existing ones, stakeholders (e.g. regulators,
legislators, program providers, pharmaceutical industries, tax payers) must be convinced
that the societal benefits from these programs is higher than the costs sustained. This study
provides insight of the willingness to pay for such programs in the region, and suggests the
annual benefits are likely to surpass the costs of implementation.
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CHAPTER 5. OVERALL CONCLUSIONS

Pharmaceuticals residues have been found over the last couple of decades in surface
and ground waters. Studies across the world have found detrimental environmental
impacts of these compounds. However, due to the low concentrations of APIs found in the
environmental and the limitation of reliable methods to monitor pharmaceutical residues
in the environment, adverse effects in the different ecosystems are difficult to determine.
Furthermore, unless species are specifically studied in a day to day basis, it is likely mild
effects will go unnoticed. Studies of pharmaceutical persistence in water sources have not
found a correlation between the most prescribed medications and their detection in the
water supply. Thus, it is suggested prescription information is a poor proxy for medicine
concentration in water. For a more accurate measure, dosage, pharmacokinetics,
wastewater treatment technology and efficiency and environmental fate need to be
considered. The available literature on these topics is still limited, thus, more research is
needed to understand the full scope of the damage of pharmaceuticals in the environment.
Unwanted and unused pharmaceuticals also represent a public health concern.
Pharmaceuticals have also been found in drinking water supply. Unfortunately, there is no
information regarding the assessment of risks to human health from long term exposure to
low concentrations of medicines in drinking water, or the possible combined effects from
a mixture of APIs. Accumulated medications in the house also represents a problem,
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increasing the risk of accidental poisoning of children and pets. However, to our
knowledge, no study has estimated the monetary cost of the damage of unsafe medication
storage. Prescription misuse and abuse is one of the most concerning public health issues
associated with pharmaceuticals. The NCHS has estimated the costs of drug abuse to the
nation in $53.4 billion dollars for lost productivity, medical costs and criminal justice costs.
Because of the negative consequences of improper storage and disposal of unwanted and
unused pharmaceuticals, medicine collection programs have been implemented at a global,
national, regional and local level to reduce the presence of APIs in the environmental and
provide proper safe and secure disposal methods. Given the lack of information of the
extent of the environmental damage and the public health implications, quantification of
the damage avoided through these programs is difficult to assess.
Even though it is difficult to estimate the monetary cost of the improper storage and
disposal of pharmaceuticals, it has been widely recognized that medicine collection
programs provide and economic benefit to society. Benefits are associated with properly
disposing unwanted household pharmaceuticals averting public health issues related to
accidental poisoning and prescription medication abuse, reducing environmental pollution
in water sources, and preventing adverse effects to organisms in the different ecosystems.
Furthermore, available literature suggests that it is very difficult to establish a correlation
between the medicines collected in these programs and the reduction in pollution in each
location given limited market economic data. Thus, to estimate the value of disposal
programs established in the Great Lakes Region, we used a non-market valuation approach.
The present study, several questions related with take-back medicine programs where
assessed. How likely are people to participate in pharmaceutical collection schemes? What
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are the factors that determine participation in the future? What are the current household
practices regarding unwanted and unused medicines? What is the societal value of
pharmaceutical collection programs?
Results from the first study suggest that to increase participation in these programs,
there should be an increase in general environmental awareness. To increase participation
in current programs, education and awareness campaigns should target younger individuals
and high incomes households. Although a majority of respondents indicated they are likely
to participate in such programs in the future, only a small percentage had actually done so,
suggesting a potential lack of knowledge about locations of these programs.
The second study estimated mean WTP, and the annual benefits these programs
provide. The benefits estimated from Scenario 1 and 3 for WTPP and Scenarios 2 and 4
for WTPV suggest that the value of pharmaceutical programs in the Great Lakes region is
between $20.75 and $41.30 million for willingness to pay per prescription and $19.70 $39.25million for willingness to pay per visit. The estimations can be used to perform a
cost-benefit analyses to assess the rate of return of funds spent on these programs. A quick
review of costs of single day events as well as permanent collection programs suggest a
favorable cost-benefit ratio for these programs in the region. This finding indicates net
social benefits of proper medicine disposal programs. From a policy perspective, we
suggest a continued support for the maintenance of current programs and the
implementation of more collection schemes in the region
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Appendix A

Survey

This survey can also be retrieved from https://purdue.qualtrics.com/SE/?SID=SV_em724dM9PhaewHr
Dear Resident,
Purdue University is studying the disposal of household unwanted pharmaceuticals
(expired and unused prescription and over-the-counter medicines in any form such as
tablet, capsule, cream, or liquid) in the Great Lakes Area. Pharmaceuticals in the
environment have negative implications for human health and ecosystems. Medicine
takeback programs provide secure collection points for proper disposal of household
unwanted pharmaceuticals to protect public health and the environment.
This study seeks to understand current methods of medicine disposal, and whether
households are willing to participate and pay for medicine takeback programs. The
results of this study will help better inform medicine takeback programs and their
effectiveness in the Great Lakes area.
This survey should take no more than 10 minutes to complete. You must be at least
18 years of age to participate. Your participation in this study is voluntary and your
responses to the questionnaire will be confidential. Your name is not required
anywhere and all survey data will be combined to ensure anonymity.
If you have any questions, comments, or concerns, please contact: Dr. Kwamena
Quagrainie (kquagrai@purdue.edu) or Sofia Vielma Delano (svielmad@purdue.edu).
1.

I confirm that I'm at least 18 years of age and would like to participate in this
research. (Check one.)
Yes (Go to question 2)
No (End of survey)

2.

What county / state do you live in? (Select the county and state.)
State __________________
County __________________

For the purpose of this survey, unwanted pharmaceuticals are defined as expired
and unused prescription and over-the-counter medicines in any form such as tablet,
capsule, cream, or liquid.
3.

Have you had unwanted pharmaceuticals in your home the past 24 months?
(Check one.)
Yes (Go to question 3.1)
No (Skip to question 4)
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3.1

Why do you have unwanted pharmaceuticals in the home? (Check all that
apply.)

The medication expired, and we did not know what to do with it
Stopped taking the medication before the supply ran out
Stopped taking the medication because of a change in medication
Received excess medication because the pharmacy kept
refilling it automatically
The user of the medication passed away.

4.

Have you ever disposed of unwanted pharmaceuticals kept in the home? (Check
one.)

Yes (Go to question 5)
No (Skip to question 8)

5.

How do you typically dispose of unwanted pharmaceuticals? (Check one.)
Wash down the sink or flush in the toilet
Throw in the trash
Take to a medicine collection program
Other (specify) ____________________________________________

6.

Typically, whose pharmaceuticals do you dispose of? (Check all that apply.)
Members of my household (including yourself)
Other relatives (non-household members)
Non-household members (e.g. friends, neighbors)
Pets

The next section asks about your participation in medicine take-back programs.
There are different ways of collecting unwanted pharmaceuticals. These include
medicine take-back programs with permanent collection boxes at pharmacies,
hospitals, other health care centers, or police departments; mail back programs; or
periodic collection events.

7.

Have you participated in any medicine take-back disposal programs? (Check
one.)
Yes (Go to question 7.1)
No (Go to question 8)

7.1

Which types of take-back program have you participated in? (Check all that apply.)
Take-away programs through the mail
Single day collection events
Permanent collection sites in pharmacies
Permanent collection sites in hospitals or other health care centers
Permanent collection sites in police departments
Permanent collection sites in other centers
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7.2

On average, how many different types of unwanted pharmaceuticals do
you dispose of per visit? (Write the number of types of prescriptions.)
________________prescription types

7.3

How long have you been participating in a take-back program?

(Write the number of months.)

______________ months

7.4

8.

Approximately, how many miles do you travel (one-way) to your main
collection point? (Write the number of miles.)
______________ miles

How likely are you to participate in a take-back program in the next 12
months? (Check one.)
Very likely
Somewhat likely
Neither likely nor unlikely
Somewhat unlikely
Very unlikely

The next section asks about your willingness to pay for medicine take-back
programs.
The presence of pharmaceuticals in surface waters is a growing environmental
concern. Let’s suppose local authorities are to charge a fee for take-back
pharmaceutical programs at local permanent collection sites (e.g., pharmacies,
hospitals, other health care centers, police departments, and hazardous waste
centers) to address this concern.

9.

How willing or unwilling are you to pay to drop off your unwanted
pharmaceuticals at permanent collection locations in your county? (Check one.)
Very willing
Somewhat willing
Neither willing nor unwilling
Somewhat unwilling
Very unwilling

10.

On average, how many different types of unwanted pharmaceuticals are you
likely to dispose of per visit? (Write the number of types of prescriptions.)
________________ Prescriptions

11.

How much are you willing to pay for each prescription that you drop off at a
permanent collection location in your county? (Check one)
$0.00
$0.01 - $1.00
$1.01 - $2.00
$2.01 - $3.00
More than $3.00
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12.

How much are you willing to pay per visit (for any number of medicines) to drop
off your unwanted pharmaceuticals at a permanent collection location in your
county? (Check one)
$0.00
$0.01 - $2.00
$2.01 - $4.00
$4.01 - $6.00
More than $6.00

This section asks for information that will help us learn about you.

13.

How important is environmental quality to you? (Check one.)
Extremely important
Very important
Neither important or unimportant
Very unimportant
Not at all important

14.

Which of the following programs does your household engage in? (Check all that
apply.)

Recycling
Composting leftover food
Water conservation (e.g., fixing leaks, taking short showers).
Energy conservation (e.g., turning off lights, turning down the thermostat).
Use of environmentally friendly products (e.g., recyclable materials)

15.

What is your gender? (Check one.)
Male
Female

16.

What is your age group? (Check one.)
18 to 25 years
26 to 35 years
36 to 45 years
46 to 55 years
56 to 65 years
65+ years

17.

Which of the following best describes your ethnicity? (Check one.)
White or Caucasian (non-Latino)
African American
Asian
Native American
Latino (White and non-White)
Multi-racial
Other (Specify) __________________________________
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18.

What is your highest attained level of education? (Check one.)
No formal education
Elementary School
High School
College
Graduate School
Professional School (e.g., Law School, Medicine)

19.

Which of the following categories best describes your total annual household
income before taxes, from all sources? (Check one.)
Up to $15,000
$15,001 to $30,000
$30,001 to $45,000
$45,001 to $60,000
$60,001 to $75,000
$75,001 to $100,000
$100,001+

20.

How many years have you been living in your present county? (Write the number
of years.)

______________ Years

21.

Including yourself, how many people live in your household? (Write the number
of people.)

_____________ People

22.

How many people from the following age groups live in your household?
(Write a number for each age group.)

_____
_____
_____
_____

23.

0 – 5 years
6 – 25 years
26 – 60 years
60+ years

Do you have any of the following pets? (Check all that apply.)
Dogs
Cats
Other (Specify) ________________________________________
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Appendix B

Forms
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